MONITORING AND CONTROL SYSTEMS FOR RECOMBINANT MANIPULATIONS

Abstract: Two types of convenient portable control cassettes for the expression of protein encoding sequences in procaryotes. Both cassettes comprise the PL promoter from lambda phage, which is controllable by means of a temperature sensitive repressor, operably linked to the ribosome binding site for N-gene (NRBS). The cassette is either bordered by restriction sites upstream of the PL promoter and immediately downstream from the NRBS permetting the insertion of a desired sequence containing its own start codon or contains an ATG start codon within the cassette and has a restriction site immediately 3' of the start codon. A novel universal dominant selectable marker cassette is also disclosed. The marker comprises the coding sequences for aminoglycoside phosphotransferase I(APH-I) which has been modified and truncated so as to render its use in recombinant vectors more convenient. The modified, truncated sequence (mtAPH-I) gene is capable, upon expression, of conferring resistance to a number of antibiotics on the host. One of these antibiotics, G418, is toxic to eucaryotic as well as procaryotic hosts. Also disclosed are fusion proteins having N-terminal sequences corresponding to a desired peptide sequence, and C-terminal sequences comprising the amino acids encoded by mtTAPH-I. These proteins are dominant selectable fusion flags which are useable in a wide variety of lacY<-> hosts. Such fusion flags permit direct selection of transformants, diagnosis of expression levels for desired seqquences, and may afford a method to purify the attached desired sequences.

Description: -l- MONITORING AND CONTROL SYSTEMS FOR RECOMBINANT MANIPULATIONS Technical Field The present invention relates to aspects of recombinant DNA technology concerned with providing control systems for expression, markers for genetic transformation and means for assessing both the control systems and transformation success simultaneously- More particularly, the invention relates to a convenient temperature sensitive control cassette, a dominant selectable marker system suitable for use in both procaryotes and eucaryotes, and versatile dominant selectable fusion flags. Background Art Alteration of the genetic makeup of a host cell is the modus operandus of current biotechnology. By suitable modification, such host cells may be caused to produce protein sequences normally unavailable in large . quantity, for example, the fibroblast or leukocyte interferons; or their metabolism may be altered so as to induce them to perform some unaccustomed function such as, for example, the conversion of starch to simple sugar. In order to perform these new protein. syntheses, the cells must be 1) made to take up the desired coding sequence and 2) be provided with control sequences which are compatible with the host in operable linkage to the coding sequences. Means must be provided to evaluate the success of both of these requirements. The present invention provides a dominant selectable marker to evaluate the first, a dominant selectable fusion flag to evaluate both simultaneously, and an improved control sequence cassette subject to such evaluation. Selectable Markers With respect to the first, a number of techniques for altering the genetic makeup of a host organism are known, including transduction and mutation. By far, however, the most useful techhique in specific control of such genetic alteration is transformation of a host cell with a suitable recombinant vector, typically a plasmid. Depending on the host cell used, a variety of transformation conditions is used. Such conditions do result in transformed cells; however, the frequency of transformation may be relatively low, i.e., about 1 cell per 10*3 for procaryotic hosts, and from one cell per 10^ to one cell per 10*2 f or eucaryotic hosts. Therefore, it is essential that a selection procedure be available td screen the population of host cells for the relatively few transformants. Typically this is achieved by including a sequence encoding a marker(s) on the transforming vector. Such a marker confers a phenotypic characteristic which will permit successful transformants to grow under conditions which are not capable of supporting the growth of the non-transformed cells. Markers useful in procaryotic systems are well known and their use has become substantially routine. Such markers include Amp R , a DNA sequence which encodes β-lactamase, an enzyme capable of degrading ampicillin, thus permitting the organism to grow in media containing the antibiotic; Tet R , an analogous sequence for protection against tetracycline; and gene sequences encoding proteins which confer resistance to chloramphenicol, neomycin, and a number of other antibiotics. Plant cell transformations have often relied on infection with vectors such as those associated with Agrobacterium tu e aciens which confer selectable (but undesirable) traits on the transformants. These traits include overproduction and premature production of plant hormones, so that tumors result. Selectable markers which are useful in other eucaryotic cells are not quite so well established. Some well known markers include the LEU2 gene which encodes the protein, β-isopropyl alate dehydrogenase, and thus permits a host organism which is normally incapable of synthesizing leucine (most commonly a (LEU2~) yeast mutant) to grow in the absence of leucine; a herpes virus thy idine kinase marker (TK) which is a sequence encoding this enzyme essential for DNA synthesis and thus permits the growth of mutant (tk~) organisms otherwise deficient in it; a sequence which encodes dihydrofolate reductase (DHFR) which permits gro'wth in DHFR deficient strains; and xanthine-guanosine ribosyl transferase (XGRT), which similarly replaces a deficiency in this enzyme. Such markers were employed in the processes for transforming eucaryotic cells disclosed by Axel, et al, in U.S. Patent 4,399,216. It will immediately be noted that eucaryotic markers typically exert their effect by replacing a deficiency in the host, in the case of mammalian or yeast cells, or by conferring undesirable characteristics in the case of plants. Thus, these markers are not suitable for selecting transformants of a population of wild-type eucaryotic cells. This is clearly disadvantageous. This deficiency has particular impact with respect to attempts to utilize recombinant techniques in industrial strains of yeast. There is a reservoir of commercial experience in handling these strains, and they have been developed to have desirable fermentation properties, e.g., high level ethanol production, formation of desirable secondary metabolic products; to have desirable physical properties, e.g., flocculation; and to grow on inexpensive minimal nutrients. The lack of a dominant (to wild type) selectable marker operable in cells confines the yeast recombinant technology to the more sensitive and fastidious laboratory strains and effectively constitutes a bar to commercial utilization of recombinant yeast. In summary, the recombinant techniques which have been, in the past decade, used successfully to transform procaryotic hosts with expression systems for desired protein products or desired metabolic characteristics, and which have relied on selection of transformants using co-transforming markers, could be extended to eucaryotic systems, including plants, mammals, and industrial yeasts, if an effective marker permitting selection of successfully transformed wild type hosts were available. Recently, a selectable marker which is effective in confering a phenotype useful to distinguish transformed wild-type from ufttransformed wild-type cells has been studied. An a inoglycoside antibiotic, G418, is toxic not only to bacteria, but to yeast, plant, and mammalian cells. Thus, a wide range of cells is unable to grow in its presence, absent a protective enzyme. The antibiotic is inactivated (via phosphorylation) by the enzyme activity referred to as aminoglycoside phosphotransferase (APH). Two different enzymes with this activity are known, APH-I and -II. The coding sequences for these enzymes are located on transposons TnβOl (also known as Tn903) (Sharp, P. A., et.al, _. J Mol Biol (1973) 75_:235, and on Tn5 (Jorgensen,, R. A., et al, Mol Gen Genet (1979) 177:65), respectively. These two enzymes are unrelated except for their ability to inactivate G418, which they, in fact, effect with differing e ficiencies; APH-I is approximately four times as effective as APH-II. In view of the toxicity of G418 to a wide variety of cells, the coding sequence for either of these enzymes becomes a candidate dominant selectable marker for use in a wide variety of hosts. The coding sequence for APH-I is. In fact, known and a 271 amino acid sequence for the enzyme has been deduced from it (Oka, A. et al, J Mol Biol (1981) 147:217. Indeed, a number of workers have cloned ' systems which permit the expression of these sequences in non-bacterial hosts (see, e.g., Hall, C. V., et al, J Mol Appl Gen (1983) .2:101). Southern, P. J., et al J Mol Appl Genetics (1982) 1_^327 showed that mammalian cells transformed with vectors containing the coding * sequence for APH-II presumably under control of a SV40 viral promoter, acquired resistance to G418. Colbere- Garapin, P., et al, J Mol Biol (1981) 150:1 disclosed expression of the APH-II coding sequence in tk~ and in monkey and human cell lines. The vectors used for transformation contained the TK promoter, presumably in « such position to effect the expression levels. However, the bacterial promoter was also retained when tk" cells were used as hosts (though not when normal cells were used), transformation efficiency was extremely low in non-tk~ cells. Jimenez, A., et al Nature (1980) 287:869 presumably achieved some expression of the APH-I gene in yeast by co-transforming the Leu~-host Saccharomyces cerevisae with a mixture of pYE13 containing a LEU2 marker and ColicinEI derivative plasm ' id carrying the desired APH-I gene sequence presumably under control of sequences either indigenous to ColEI or to the enzyme encoding segment. Expression was shown only following selection for Leu + . Thus, Jiminez did not disclose a method to utilize the APH-I gene as a selection tool. Whether or not selection could have been made using G418 resistance as a criterion is unclear. No effort was made by Jimenez to place the coding sequence under the control of a yeast promoter. It would thus be unlikely that the gene expression levels would be sufficient to provide amounts of protein effective against selection pressure (as opposed to the ability of selected cultures to exhibit G418 resistance). Fraley, R. T., et al Proc Natl Acad Sci (USA) (1983) 8 :4803 describe the utilization of the coding sequence from the APH-I gene under control of a promoter derived from a bacterium capable of infecting plants, and terminated with a 3' untranslated terminating sequence also active in plants. Presumably under such control, expression of the gene for this enzyme, and also for the related APH-II analog was achieved in petunia cells. Finally, U.K. patent application GB2100738A, published January 6, 1983, discloses expression of both the gene encoding APH-I and that encoding a protein which confers resistance to hygromycin B under the control of an SV40 promoter. Expression was achieved both in yeast and in mammalian mouse Ltk- cells. Webster, T. D., et al. Gene (1983) 26:243 disclose the use of native APH-I as a selection marker useable after 18 hours from transformation in laboratory yeast strains. In all of the above cases, the coding sequence for the desired G418 resistance gene was preceded by an uncontrolled number of nucleotides between the natural ATG start codon and the control sequences and, indeed, the nearest upstream convenient restriction site which might permit manipulation with respect to such control sequences. As a result, random occurrences of ATG codons and TGA, TAA, or TAG termination codons in various reading frames in this preceding sequence interfere with a precise reproducible translation of the desired sequence. The selectable G418 resistance gene of the present invention is modified and truncated so as to overcome these problems, and is also adaptable as a fusion flag. Simultaneous Selection and Expression Evaluation As the sequence encoding the desired peptide must be provided with control sequences compatible with the transformed host in a configuration which will effect the desired expression, preferably at an optimal level, it is also highly desirable to have access to a means for gauging the operability of such configurations as well as for selecting successful transformants. These capabilities are available separately, but not in combination, with one exception - lacZ fusion flags. However, lacZ fusion flags are operable to provide such a combination of effects only in lacY+, lacZ" hosts. This requirement limits their usefulness with respect to their dual capabilities to a very narrow range of exclusively bacterial hosts. It would be desirable to have a readily assayable "flag" which will simultaneously serve as a dominant selectable marker for successful stably transformed hosts other than those of this limited range. Such a flag when fused to the desired sequences would be capable of simultaneously selecting the desired cells, and assessing the activity of the control sequences for the production of a desired sequence therein. If the flag also encodes an enzyme with a high affinity for substrate, it has the additional advantage of offering a superior means for purification of the fused protein sequences. The one successful fusion flag, well known in the art, is the lacZ fusion. It has long been known that the amino terminal portion of beta-galactosidase is not essential for enzymic activity (see, for example, Miller, J. H., et al, The Operon (1980) Cold Spring Harbor Laboratory, page 245. Furthermore, there are convenient indicator media available such as, for example, media containing 5-bromo-4-chloro-3-indolyl-beta-D-galactoside (X-gal) a substrate for beta-galactosidase which, when hydrolyzed, produces a blue dye. Thus the enzymic activity can be detected visually by the presence of blue colonies on the medium (in certain circumstances) or can be assessed quantitatively by the intensity of the blue color produced by extracts. This fusion flag has been used extensively to study expression in bacteria, in yeast (Guarente, L., Meth Enzymol. (1983) 101, p 181; Rose, M., et al, (ibid.) p 167; and in mammalian cells (Hall, C. V., et al, supra). Indeed, this method is suggested in the standard molecular laboratory manual of Maniatis, T., et al (Cold Spring Harbor Laboratories, (1982) p 431). The difficulty with using the lacZ fusion as a diagnostic for desired expression lies in its inability to behave simultaneously as a dominant selectable marker in most cells. Only under certain limited conditions can this function be served. Selection operates by using a medium which contains only lactose as a carbon source so that only cells capable of hydrolyzing lactose - i.e.', expressing the lacZ gene can survive. This provides selection of transformants only if the host cells are lacZ". It is easy to obtain bacteria (which are haploid) which are, indeed, lacZ" and this accounts for the popularity of this fusion flag for use in procaryotes. The cells must also be capable of lactose uptake, which requires an additional permease enzyme encoded by the lacY gene in certain Gram negative bacteria, in particular, E. coli. This enzyme and the sequences encoding it are lacking in eucaryotic cells and in other bacteria such as some strains of Streptomyces. While it is a simple matter to destroy the lacZ gene expression capability of haploid cells normally capable of metabolizing lactose, it is difficult or impossible to provide lacY+ mutations in cells lacking this gene even in other bacterial strains. Therefore, for most cells otherwise useable as hosts, lacZ fusions cannot be used as dominant selectable markers, since even successfully transformed cells lacking the permease will fail to grow on lactose containing media. Additionally, the lacZ fusion flag is less adaptable than other enzymatic activities for use in purification. Although techniques for using this fusion in affinity chromatography are known (Steers, et al, Meth Enz (1974) .34:350), construction of competitive substrate analogs which bind to the enzyme but are not hydrolyzed is required. The normal substrates for this enzyme are only lactose and water, therefore it is diffi¬ cult to find conditions whereby the β-gal protein is tightly bound to an affinity column containing the lac¬ tose substrate and then later released. There is no convenient way to withhold the additional substrate (water) and thus prevent the destruction of the binding moiety on the column. Also, the size of the protein is so large (1015-1020 amino acid residues in comparison with the substantially smaller 261 amino acid mtAPH-I sequence illustrative of this Invention) as to make its use in this way comparatively troublesome. Raster, R. R., et al, Nucleic Acids Research (1983) ^1:6895 have attempted to use a sequence encoding hygromycin B (Hm) as a fusion flag to assess the regulation of the lac promoter/operator in transformed E. coli. Hygromycin B, as set forth above could conceivably be used as a dominant 'selectable marker in a broad spectrum of host cells, as it destroys an antibio- tic toxic to many hosts including eucaryotes. The Raster reference indicates that the hygromycin B sequence ligated to the 5' portion of the lacZ sequence shows higher plating efficiencies in the presence of IPTG (a standard inducer of the lac promoter) than in its absence. However, the meaning of such results is clouded, because even when grown in the presence of IPTG, previously selected cells which, in the presence of the antibiotic should have a plating efficiency of 100%, gave plating efficiencies of 0.1% or less. Indeed, only one specialized construction was able to utilize the selectable marker capability of Hm R even in bacterial hosts. Further, no evidence was provided that a fusion protein was synthesized. The present invention uses the above described G418 resistance conferring marker to extend the convenience and utility of a lacZ-like dominant selectable fusion flag to a broad spectrum of host cells with the additional advantage of providing a purification tool for desired fused sequences. Control Sequences The dominant selectable marker of the invention also provided a useful tool to obtain a highly efficient temperature-sensitive control cassette. This cassette also forms part of the invention. Control sequences are conveniently provided as portable cassettes which could be shuttled between plasmids to precede protein encoding sequences at will. Such portable sequences are, in fact, known in the art. For example, the trp promoter/operator system, including its ribosome binding site and some leader sequence codons, has been described in detail (Goeddel, et al, Nucleic Acids Res (1980) 8.:4G57). In addition to the convenience of a portable sytem, however, it is also required that the control system be regulatable by control of external parameters. Because bacterial hosts are often called upon to produce proteins which are not endogenous, premature production of these proteins during the growth phase of the culture may have an adverse effect on the health of the host cells. In order to obtain healthy growth, as well as a good quantitative protein production, it may be necessary to repress the expression of the desired gene during the growth phase of the culture, and then to permit expression after the growth phase has been substantially completed. The presently available portable promoter systems, while subject to such control, are imperfect in their degree of attainment. For example, the above-mentioned trp promoter is regulated in response to the presence or absence of tryptophan in the medium. The promoter is turned on in the absence of tryptophan, but repressed in its presence. Neither a complete "on" or "off" position is attainable with such a promoter, however. For most bacteria, the indigenous repressor gene does not provide sufficient repressor to interact completely with the desirable higher levels of promoter/ coding sequence constructs present on multi-copy plasmids within the cell. Conversely, since many proteins, desired to be synthesized, themselves contain tryptophan, it is not possible to delete tryptophan entirely from the medium when they are to be produced. Even approximate control is troublesome as medium exchange is often required to change the tryptophan level sufficiently. The λ phage promoter, P L , however, is subject to more finely tuned and convenient dontrol, because the repressor which binds to its operator sequence can be temperature sensitive. The ?_ operator is repressed at low temperature by repressor proteins such as CI857 which are synthesized by appropriate mutant host cells. However, at higher temperatures, this repressor protein is deactivated, and the promoter is switched on. Thus, simply by raising the temperature of the culture, the synthesis of the desired protein sequence can be turned on. The P L promoter in its native environment operates to synthesize, among other things, an "N-gene" protein whose translation is controlled by an N RB g ribosome binding site. In the phage, the N-gene is the first coding sequence in the polycistroniσ message under the control of the P L promoter. _ promoter alone, and P-Q promoter on a sequence with the RBS (which is not functionally utilized) have, indeed, been used previously to control the expression of genes encoding E. coli or foreign proteins in bacterial systems. See Shimatake, et al. Nature (1981) 292:128; Remaut, E., et al, Nucleic Acids Res (1983) 3^:4677; Remaut, E., et al, Gene (1983) 22: r.03. However, this control system has not been packaged into a readily transposable segment which can be shuttled from one expression vector to another with ease. In fact, disclosures of the location of the NRBS sec 3 uence -** n E. coli lambda phage, and therefore the composition of the disclosed sequence, have been grossly in error (Scherer, G. F. E., et al. Nucleic Acids Res (1980) £:3895 at p 3898). By employing the selectable G418 resistance marker, the exquisitely regulatable P^ BS ontr °l sequence has been packaged into a conveniently excised segment in suitable source vectors so that it can be used either by placing the PL RBS se< 3 uences in front of an ATG start codon, or the P L NRBS can brin 9 with t a bl nt 3' end ATG for ligation onto N-terminal blunt-ended coding sequence. Disclosure of the Invention The present invention provides a truncated coding sequence for APH-I (hereinafter sometimes called the Ran gene) which contains convenient restriction sites immediately upstream of the start codon. The coding sequences of this marker can be used as a cassette and integrated into plasmids containing control sequences such as promoters and transcription termination sequences which are effective in any desired host organism. Thus, the coding sequence can be shuttled from a carrier vector into a vector adapted to replication and expression in yeast or one which is adapted to expression and replication in a number of other types of organisms such as procaryotes, plants, and mammalian cells. In providing this cassette, the invention also permits construction of fusion flag proteins which contain the sequences conferring G418 resistance conjugated to the C-terminus of a desired peptide sequence. This desired sequence may contain a particular antigenic component or may be unstable in the cellular medium by virtue of its size, and its synthesis as a fusion protein will thus provide necessary immunogenicity or stability, respectively. Such fusion flag proteins have additional utilities: 1) they provide assay systems which are capable of assessing the effectiveness of expression control sequences which are operably linked to the desired peptide, and 2) they can be used as an affinity recognition sequence for purification. The marker cassette of the invention has also been used as a tool in construction of a superior regulatable, portable procaryotic 'control cassette. Thus, in one aspect, the invention relates to a DNA sequence encoding a modified truncated Ran gene and having at least one cassette-unique restriction site upstream of, and proximal to, the ATG start codon of the modified, truncated Ran gene. In two preferred embodiments, the truncated Ran gene is-missing the codons 2-9, and 2-10, respectively, and has been modified to destroy the Hindlll and X al sites at codon positions 184/185 and 102/103 of the non-truncated gene sequence. Thus, this aspect of the invention provides a modified, truncated Ran gene (mtRan or mtAPH-I) cassette which is adaptable to a variety of uses. The mtAPH-I cassette is also used to construct a dominant selectable fusion flag which permits both selection of transformed cells and facile diagnosis of the performance of a desired expression system in its new environment. The fusion flag provides a one step procedure whereby the selection and quantitation so conveniently provided by the lacZ fusion to a limited group of Gram negative hosts is extended to other bacterial systems which lack the required lactose permease, and to eucaryotic cells in general. The choice of host cells available for efficient expression of desired coding sequences is expanded beyond the limited domain of E. coli and certain other bacterial permease- containing strains to include mammalian cells, yeast cells, plant cells and other types of bacteria such as strains of Streptomyces, a genus widely used for antibiotic and amino acid production. Thus, in another aspect, the invention relates to a fusion protein which is operable as a dominant selectable marker in lactose permease deficient (lacY") cells and which has quantifiable enzymic activity. (Of course, it is operable in lac Y + cells as well.) LacY" cells include all of the foregoing alternate hosts set forth in the previous paragraph. Enzymic activity provides a means for assessing the amount of biologically active protein produced. The mtAPH-I cassette was also used as a marker in the process of constructinig a superior procaryotic control cassette. This aspect of the invention relates to a DNA sequence comprising the PL promoter operably linked to the- RB g having a restriction cleavage site within 6 bp downstream of the NRBS' and to vectors containing the sequence. The resulting vectors may, of course, no longer contain the restriction cleavage site. In addition, a DNA sequence comprising the P L promoter operably linked to the N BS and to an ATG start codon, the sequence having a restriction site within 6 bp downstream of the ATG, is part of the invention, as well as to vectors containing this sequence where, again the cleavage site may now be absent. In other aspects, the invention relates to cloning and expression vectors which contain the modified, truncated Ran gene cassette of the invention operably linked to control sequences suitable for a particular host. Such vectors may also include expression sequences for a desired peptide; the presence of an effectively expressible mtAPH-I thus serves to provide a selection tool for cells capable of providing the desired protein. In other vectors of the invention, a DNA sequence encoding a desired protein is placed in reading frame with the modified, truncated Ran gene coding sequence, and operably linked to suitable control sequences, so that expression of these sequences results in the selectable fusion flag. Other aspects relate to host cells transformed with the above mentioned vectors, to the novel protein products of transformants derived from these vectors, and to methods of obtaining such vectors, transformants, and fusion proteins. In still another aspect, the invention relates to the uses of the mtRan gene cassette as a dominant selectable marker in both procaryotic and eucaryotic cells, and to use of the fusion proteins produced as tools for stabilization or purification of a desired contained peptide sequence, for conferring immunogenicity on the desired sequence or as dominant selectable fusion flags. Brief Description of the Drawings Figure 1 shows the construction of pMCR4.1 and pMCRl.4. Figure 2 shows the construction of pFC19. Figure 3 shows the construction of pFCll. Figure 4 shows the construction of pDG144. Figure 5 shows the 5' terminal coding sequences for the Ran gene in pNG56, pMCR4.1 and pMCR1.4, along with the corresponding N-terminal animo acid sequences, and the levels of Ran resistance conferred on E.coli MM294 by transformation with these vectors. Figure 6 shows the results of 2-D electrophoretic analysis of protein extracts of E.coli transformed with pNG56, pMCR4.1 and pMCR1.4 and labeled with 35s-methionine. Figure 7 shows, schematically, the features of. PDG148, pDG149 and pDG151. Figure 8 shows the results of G418 direct selection of a laboratory yeast strain transformed with various mtAPH-I expression plasmids. Figure 9 shows the results of G418 direct selection of industrial yeast strains transformed with pDG149 mtAPH-I expression plasmid.' Figure 10 shows a autoradiograph of 2D gel electrophoresis performed on transformed yeast cell extracts, labeled with 35s-methionine. Figure 11 gives the results of a one- dimensional Western analysis of yeast extracts containing various fusion proteins. Figure 12 shows the construction of pFC54. Modes for Carrying Out the Invention A. Definitions As used herein, "Ran gene" (or APH-I gene) refers to a DNA sequence encoding a protein which is capable of exhibiting the functional* characteristics of APH-I. These functional characteristics include inactivating a series of antibiotics, and APH-I is distinguishable from APH-II and from the enzyme inactivating hygromycin B by virtue of the spectrum of activities it exhibits. Thus, although termed the "Ran gene" herein for brevity and convenience, the protein encoded by this gene is considerably less effective in inactivating kanamycin than is the related protein APH-II. It is, however, somewhat more effective in inactivating neomycin and considerably more so in inactivating lividomycin against which its analogous counterpart is completely inactive. However, the protein encoded by this gene is approximately four times as effective against G418 as the APH-II enzyme. This is particularly advantageous because of the toxicity of G418 against a wide range of cells including eucaryotes. "Truncated Ran gene" or tAPH-I refers to a Ran gene coding sequence which has been abbreviated in some fashion. Generally, this terminology is used with respect to the truncated forms disclosed by this invention: i.e., the "V2-9" and "V2-1Q" deletions. However, other deletions which retain the functionality of the resulting protein are also within the scope of the invention. "Modified Ran gene" or mAPH-I gene refers to a Ran gene or, if appropriate from the context, truncated Ran gene wherein the base sequence is altered so as to allow the amino acid sequence encoded to remain the same while altering the restriction site pattern within the ' gene. Specifically, it refers to such modifications which eliminate restriction sites within the gene which sites would otherwise destroy the unique nature of a cassette-unique site (defined below). "Modified, truncated Ran gene" or mtAPH-I refers to a Ran gene which is both modified and truncated as described in the preceding two paragraphs. "Cassette-unique" restriction site refers to a site for specific endonuclease digestion which appears only once in the DNA sequence desired to be excised. Thus, for example, relevant to the present invention, the Ran gene encoding sequence is modified to remove any recognition sites which are identical to those available to excise or manipulate the cassette. "Proximal to" when used to describe the location of a cassette-unique restriction site in relation to a ATG start codon for a desired coding sequence means that the site is positioned with respect to the ATG start codon in such a way that there are no intervening ATG or stop codon sequences between the site and the desired ATG start codon. In addition, the site must be sufficiently close to the desired ATG start that it permits operable linkage (as defined below) to a promoter sequence and, if applicable, a ribosome binding site sequence upstream of the site. Thus, two criteria must be met: lack of alternate false- start or stop signals, and reasonable spacing to permit the desired coding sequence to be expressed when religated into appropriate expression vectors. Of course, the restriction site may be lost upon ligation into such vectors. "Quantifiable enzymic activity" refers to the ability of a protein sequence to be assayed quantitatively by virtue of its ability to catalyze a reaction whose course is measureable. This would, in principle, include any enzyme, and is specifically intended to include those whose activity is assayed by means of, for example, use of color generating substrates and by conversion of radioactively labeled substrates into easily separable radioactive products, as well as to those assayed by the ability to confer resistance to varying levels of antibiotics. The availability of means for quantitating the proteins obviates the need to assess their amount by much more tedious procedures such as their reaction with labeled antibody or the intensity of a stain of the correct molecular weight on a gel. Also, assay by methods dependent on enzymic activity assures that the protein produced is in biologically active form; immunoassays and stains showing the presence of protein correlating to an expected molecular weight do not. "Dominant selectable marker" refers to conferring a phenotypic characteristic which is capable of selecting (as opposed to screening) successful transformants. This characteristic permits growth and reproduction on media which are incapable of supporting the growth of untransformed cells. Such markers can operate in either positive or negative ways — i.e., to enable utilization of particular metabolites, or to confer resistance against growth inhibitors. For example, the lacZ gene confers the ability on lacY + cells to grow on lactose as the only carbon source. The and etR genes confer the ability to grow in the presence of these antibiotics. "LacZ" and "lacY" refer to genes or portions thereof which confer functional beta-galactosidase and lactose permease activities respectively on cells expressing them. "Fusion" refers to uninterrupted sequences of amino acids or of nucleotides having a "desired protein portion" and a fusion flag portion. The "fusion flag portion" confers the properties of capability to behave as a dominant selectable marker and quantifiable enzymic activity on the entire sequence. It can thus be referred to as the "enzymic/marker" portion, as well. Generally, the sequence which comprises the fusion flag portion corresponds to a complete or partial sequence of an enzyme which confers a selectable property on the host, such as the aminoglycoside phosphotransferases referred to above. Because there is a one-to-one correspondence between nucleotide sequence in the gene and the resulting amino acid sequence in the protein, the terms used in describing both the gene and the encoded protein are often used interchangeably. Thus, "selectable marker", "fusion", "fusion flag", "fused sequences" and the like refer, depending on context, to either peptide or gene. "PJ-N BS cassette" refers to a DNA sequence which contains the P L promoter sequence operably linked t0 N RBS » which cassette is bounded by restriction sites upstream of the ϊ?_ promoter sequence and downstream from the N RBS sequence. While the exact location of the upstream restriction site is not of importance, the location of the downstream site must be close enough to permit operable juxtaposition to an ATG "start" codon. Thus, the downstream restriction site must permit cleavage within 6 bp of the last base pair of the RBS SO that the entire cassette can be conveniently inserted within workable distance of an ATG start codon for the desired protein. " P L N RBS ATG-cassette" refers to a DNA sequence which contains a x?_ promoter operably linked to the NRBS coding sequence and to an ATG start codon. The cassette contains a downstream restriction site which permits cleavage within 6 bp 3' of the G of the ATG start codon. This permits convenient ligation of the blunted cassette into reading frame with a desired coding sequence. Cleavage "within 'n' bp" of a given location requires that at least one of the two strands be so. cleaved. As is known, most restriction enzymes catalyze cleavage in a jagged pattern, the cleavage site in one strand being separated by several bp from the cleavage site in the complementary strand. To fit the herein definition, only one of such sites needs to be within the required "n" bp. The vectors containing the cassettes of the invention may or may not contain a cleavage site as described above. Depending on the protocol for ligation ' of the cassette into a recipient vector, the site may or may not be lost. "NRBS" and " N RBS corresponding sequence" or "ribosome binding site" and "ribosome binding site corresponding sequence" are also used inter¬ changeably in that the embodiment intended will be clear from the context. Thus, when NRBS is used fco describe a portion of DNA, clearly " ^g corresponding sequence" is meant. "IL-2" refers to proteins having sequence ho ology with, and the functionality of, interleukin-2. Proteins having the precise sequence of native IL-2 are included, as well as sequences containing sequence modifications which do not destroy activity. In the illustration set forth below, a modification or "mutein" having a serine residue rather than a cysteine at position 125 is used. "Operably linked" refers to constructions wherein the components so described are juxtaposed in such a way as to permit them to function in their intended manner vis-a-vis each other. Thus, a promoter operably linked to a coding sequence refers to a promoter which is capable of effecting the transcription of the desired coding sequence. "Suitable for" or "appropriate to" eucaryotic or other cells refers to control sequences which, when found in nature, would ordinarily control the expression of coding sequences in a particular type of cell or are more than marginally effective in doing so. For example, promoters suitable for eucaryotic cells include the SV40 early promoter which is, in fact, a viral promoter. However, the mode of operation for the virus is to cause transcription to occur by virtue of this promoter using the machinery of a mammalian cell. Similarly, the nopaline synthase promoter of Agrobacterium tu efaciens operates effectively in the eucaryotic plant cell it infects. Various yeast promoters such as LEU2 or ENOl, are found to effect expression of proteins in yeast, and hence are "appropriate to yeasts". To the extent any particular control sequence(s) effect successful expression of an operably linked sequence in a host, such sequence(s) would be considered to fall within this definition. "Control sequences" refers to whatever is required to effect the expression of a coding sequence in connection with a particular host.' It is clear that in both procaryotic and eucaryotic systems appropriate promoters, with or without operators, are required. Procaryotic hosts also require presence of a ribosome binding site. It appears that eucaryotic cells generally require, for effective expression, a polyadenylation signal to assure that the mRNA transcribed from the gene sequences is transported out of the nucleus and translated. The nature of this process is not well understood, but it is known that certain terminator sequences which include polyadenylation signals are necessary for effective production of desired proteins in eucaryotic hosts. Suitable "signal" sequences include the ENOl 3' untranslated region from the ENOl gene, and the nopaline synthase sequences obtainable from Agrobacterium plasmids which normally operate in the plant cell host. "Polyadenylation signal" or "terminator" is intended to include whatever is required in these sequences, not to be limited simply to this particular function. This definition is necessitated by the current state of knowledge in the art, wherein the " relevance of sequences in addition to the polyadenylation signal is unclear. "Recombinant host cell" refers to a cell which has been transformed with DNA sequences which have been manipulated by recombinant techniques. "Cells" and "cell culture" are used interchangeably where the context so permits, and these terms include the progeny of any specific cells referred to. Thus, these terms refer to cells whether separated from or suspended in the medium and whether living or dead. These terms thus include progeny of an original transformed cultures, which progeny may differ by mutation from the parental cells. ■ B. General Description The modified, truncated Ran gene cassette of the invention can be used in a variety of contexts and constructions. Its advantages, as stated above, are its universality as a marker system in a wide variety of transformed hosts, its transportability from one expression vector to another, and its provision of proximal 5' restriction cassette-unique endonuclease recognition sites so as to permit its inclusion as a C- terminal sequence fusion protein or its operable linkage to suitable control sequences. Thus, it may be used as follows: 1. It may be ligated in operable linkage to promoters (and/or terminators) suitable to a variety of host cells, as part of expression vectors, and then used as a dominant selectable marker for direct selection of successful transformants in the same sense ampicillin resistance can be so used in the commonly employed procaryotic transformations. Such expression vectors include, for example, pFC19 and pDG151, wherein the gene is under the control of the trp promoter system. These also contain restriction sites for insertion of other expression sequences, thus coding and control sequences for a desired protein may also be inserted into them, and the phenotypic property conferred by the ratAPH-I gene used as a selectable marker for successful transformants. These vectors are suitable for procaryotic expression, as is P^Ran illustrated herein. (ρP L Ran is also a useful tool in preparing the control cassette of the invention.) Analogously, for eucaryotes, pDG148 contains the modified, truncated Ran cassette under control of SV40 promoter, and convenient sites for insertion of additional expression sequences; similarly pDG151::RSV contains the Rous Sarcoma Virus "LTR" promoter. Plasmid pDG149 contains the modified, truncated Ran cassette under control of the enolase promoter and terminator from yeast; pDG150 is a slightly smaller form of pDG149 wherein the bacterial-derived sequences preceding the yeast enolase promoter sequences are deleted. These plasmids and others like them are, of course, merely illustrative, and they can be used as backbone expression vectors which contain a simple index of successful transformation in a variety of hosts which can be, then, employed in tranformations to obtain production of desired protein sequences encoded under suitable control in inserts made to these vectors. In order to function in this way, the vectors need only have an origin of replication or other means of replication (such as integration into the genome) compatible with the host, the mtAPH-I sequence operably linked to control sequences suitable to the host, and at least one unique restriction site not present in the mtAPH-I expression sequences. 2. The truncated Ran sequence can be used as a fusion flag when a suitable expression sequence is ligated upstream of its 5' terminus. Because it can be (and, indeed, has been) provided convenient restriction sites immediately prior to its ATG start codon, construction of such fusion proteins is feasible. Thus, for example, the plasmids, pDG144 and pDG151, permit insertion of the initiation control and coding sequence for portions of, for example, a LEU2 gene (which can be expressed both in E. coli and in yeast) and results in a fusion between the sequence encoding the enzyme, β-isopropyl malate dehydrogenase (permitting leucine independence in LEU2~ (yeast) and leuB~ (E.coli) hosts), and the modified truncated Ran sequence. The effect of changes in the control system for th© LEU2 gene can then be studied by using the expression of the Ran sequence as an indicator, since the level of G418 resistance can be used as an index for level of expression of the gene encoding the fused peptide sequence. Again, these embodiments are illustrative only; the requirements for the host vector are ability to replicate, to express mtAPH-I in a cloning (not necessarily the desired) host, and a cassette-unique restriction site upstream of, and •proximal to, the mtAPH-I ATG start codon. This permits the construction of expression vectors for fusion proteins wherein the N-terminal sequence and 5' control sequences suitable to the intended host are linked to the mtAPH-I coding sequence at the C-terminus. For eucaryotic hosts, it may also be required and probably desirable to include 3' control sequences downstream from the mtAPH-I codons, however, this is not at present clear. Additional utilities of the resulting fusion proteins are suggested in paragraphs 3-5 below. For use as a "fusion flag", the fusion protein must have important characteristics: it must behave as a dominant selectable marker, and it must be quantifiable by enzymic assay. mtAPH-I fused to an additional amino acid sequence is capable of conferring G418 resistance on eucaryotic host cells; thus, the mtAPH-I sequences retain their assayable enzymic activity (by increasing the levels of G418 present in the medium, the level of enzyme present can readily be assessed) and behaves as a dominant selectable marker in cells sensitive to G418 toxicity which makes it applicable to a broad range of hosts. (Other appropriate fusion partner sequences can also, of course, be used. For example, hygromycin B is an antibiotic toxic to a wide range of cells including eucaryotes, and a sequence encoding the aminoglycoside phosphotransferase capable of inactivating the antibiotic is also capable of behaving as a dominant selectable marker in a wide range of cells. This same activity confers quantifiable enzymic activity on the protein. An additional APH enzyme capable of conferring G418 resistance on eucaryotes as well as procaryotic cells is the APH-II derived from Tn5 (supra). Other examples include the EcoGPT gene which, when transformed into eucaryotic hosts, confers ability to overcome inhibition of the salvage pathway for DNA synthesis by mycophenolic acid. Therefore mammalian host cells, which are incapable of growing in the presence of mycophenolic acid in certain selective media where the normal DNA synthesis pathway is blocked (for example, HAT media), can be selected for EcoGPT transformants by the ability to grow in such selective media in the presence of mycophenolic acid. Any DNA sequence which, when expressed, will confer a phenotypic characteristic capable of conferring selection on a host lacY"" cell is useable. Of these, however, those which operate to select in wild type cells are preferred to those which operate only in host cells with selected deficiencies because of their wider applicability.) For all of the foregoing and other specified fusion flag portions, sequences (in the gene or resulting peptide) will be referred to by the type of enzymic activity displayed. The sequences need not correspond precisely to native sequences so long as activity is retained. The enzymic activity is assayable by any means known in the art. With respect to antibiotic resistance, this may be preliminarily assayed by the ability of the cells to grow in varying levels of the antibiotic. However, alternate and more direct means of quantitation are generally available. For example a summary of methods for assay of aminoglycoside modifying enzymes is given by Haas, M. J., et al, Meth Enz (1975) 3:611. For the mtAPH-I sequences illustrated below, assessment of activity can be made by utilizing labeled substrate and measuring the formation of labeled product. Extracts of cells producing APH-I are incubated with a suitable substrate such as neomycin, kanamycin, lividomycin, or G418 and 32P-ATP. The transfer of P-32 from ATP to antibiotic can then be assessed by measurement of radioactive phosphate bound to phosphocellulose. (Phosphocellulose binds the antibiotic, but not ATP). While this method as used directly on extracts or whole cells is subject to complication due to the presence of cold ATP or of ATPase in the cell extract, this defect can be remedied in a convenient fashion by adsorbing the extract onto a sepharose or other suitable support column containing the covalently attached antibiotic substrate such as a neomycin-sepharose column. 32P-ATP can then be added to the immobilized neomycin/enzyme complex and the level of enzyme activity determined simply by assaying the level of bound radioactive neomycin. Alternatively, the specifically bound enzyme or fusion protein can be eluted with high ionic strength buffer (e.g., containing 1.5 M RC1) containing neomycin (e.g., 0.3 mM) and subsequently assayed by conventional methods (Haas, M. J. (supra)). An alternative approach is to provide labeled kanamycin, neomycin and the like and to measure labeled phosphosylated substrate. The practice of this approach is well within the skill in the art, given suitably labeled antibiotic, and is presently disadvantageous only because of the commercial unavailability of such substrates. 3. By using, as the N-term.inal fusion partner, the codons for an antigenic sequence, an immunogenic fusion protein will result, thus permitting the modified, truncated Ran sequence to serve to confer both a • selectable characteristic on the transformant and added immunogenicity on the antigen. This is especially significant since antigenic determinants are often quite short amino acid sequences which are not immunogenic. Such immunogenic proteins are particularly useful for diagnostic and therapeutic (vaccination) purposes. Thus, in addition to, for example, pLR11.17, pLR51.57, and other fusion protein encoding vectors illustrated herein, alternate vectors containing control and coding sequences for other N-terminal fusion partners such as, for example, the antigenic determinant peptide portions of viral coat proteins, may be constructed using means known in the art. 4. The fusion proteins made possible by the modified, truncated Ran cassette of this invention can also be produced as stabilized forms of short polypeptide segments as N-termini in a variety of hosts. 5. The fusion proteins can be purified by aminoglycoside affinity chromatography by taking advantage of the specific aminoglycoside binding ability of the mtAPH-I portion of the peptide. Conditions for affinity chromatography based on such enzyme substrate bending are much milder than those associated with antigen/antibody affinity separations, thus minimizing the danger of destroying the desired protein when eluting it from the support. This approach, for mtAPH-I fusions takes advantage of a requirement for more than one substrate for the enzymically catalyzed reaction. The enzyme whose purification is desired can be adsorbed from a mixture using a support to which has been bound only one of the substrates, and it can 'then be removed by supplying the additional or same substrate to release the enzyme. This approach is more practical for the fusion flags of the invention than for the "traditional" lac flag, since beta-galactosidase has as substrates lactose and water. Since it is difficult to work with proteins in non-aqueous media, the second substrate (water) is automatically present and a column comprising solid support with bound lactose is not successful in selectively adsorbing beta-galactosidase from aqueous media. However, for the invention fusions two non-water substrates are required and the second substrate can be used to effect the elution of the enzyme from the column. Thus, a support, such as polyacrylymide or sepharose containing bound antibiotic such as neomycin or kanamycin can be used to adsorb the mtAPH-I protein from the medium. The enzyme can be specifically eluted by supplying the other substrate for the reaction, ATP, or eluting with a high concentration of neomycin (e.g., 0.3 mM). Also as mtAPH-I is a comparatively small protein (261 amino acids) and purification of its fusions is easier, as they do not resist entering stacking gels. The specific embodiments described below illustrate the construction of vectors which are useful in the foregoing utilities. pFC19 is particularly useful for diagnosis of regulatory systems in procaryotic hosts. It contains the modified, truncated Ran sequence immediately downstream from a Hindlll site, a cassette- unique restriction site which is the 3' end of an EcoRI/ Hindlll trp promoter/operator cassette and proximal to the ATG start codon. (The native Ran coding sequence is modified to destroy the Hindlll site at codons 184/185.) Thus, expression of the modified, truncated Ran gene sequences can be used to indicate the power of substitute control systems for the trp cassette; PDG144 provides a versatile source for the modified, truncated Ran cassette of the invention. In the DNA sequence immediately 5' of the ATG start codon of V2-10 truncated Ran coding sequence, there are convenient Hindlll, BamHI, Smal, and EcoRI cleavage sites; the Hindlll (codons 184/185) and Smal (codons 102/103) sites in the native coding sequences have been destroyed. Thus, in addition to promoters, desired coding sequences for fusion proteins having a variety of 3' restriction sites can be placed in reading frame preceding the ATG start codon. pDG148 and pDG151::RSV illustrate the insertion of the modified truncated Ran cassette into vectors containing (in pDG148) a mammalian origin of replication (from SV40) and SV40 or RSV derived transcription control sequences. By placing a desired coding sequence under the control of an additional eucaryotic promoter, and inserting the package elsewhere in the pDG148 or pDG151::RSV plasmids, pDG148 or pDG151::RSV can be used as suitable backbone fragments containing a dominant selectable marker. Also, by insertion of a desired protein coding sequence into the convenient cassette-unique Hindlll site between the promoter and the ATG codon of the truncated modified Ran gene with or without its own promoter sequence, a desired protein sequence can be produced in eucaryotic cells as a fusion protein, and successful expression of the sequence detected by use of the Ran gene as a fusion flag.. In either case, by increasing the concentration of G418 in the medium in which the cells are grown, those which are particularly successful in producing the Ran gene product, and, therefore, in producing the desired protein sequence can be selected. pDG149 and pDG150 illustrate analogous constructions which are particularly appropriate in transformation of yeast. The plasmids contain the modified truncated Ran sequence under control of the enolase I promoter and termination sequences. Insertion of a desired coding sequence under control of an additional yeast promoter at one of the other restriction sites in these plasmids can be used to produce a desired protein with the aid of selection for successful high copy number transformants utilizing increasing G418 concentration in the medium. The foregoing plasmids are, of course, merely illustrative of vectors suitable for eucaryotic hosts which will accept additional expression cassettes or coding sequences and provide the ability to replicate in eucaryotes and effect the production of a dominant selectable marker. Analogous plasmids can be constructed, for instance, by using mtAPH-I cassettes encoding the V2-9 protein constructed from MCR1.4 (see below) in a manner precisely similar to that which was employed in constructing the mtAPH-I cassette encoding a V2-10 protein from MCR4.1. pDG151 is a modification of pDG149 which is even more convenient for construction of fusion proteins ' having the mtAPH-I sequence at their C termini. By providing a multiplicity of cassette-unique restriction sites 5' of the mtAPH-I gene, partial or complete coding sequences under control of suitable promoters can be fused to the mtAPH-I coding sequences which, in pDG151, have been provided with a terminator operable in yeast, resulting in a fusion protein with a kanamycin/G418 resistance fusion flag. In addition, three vector plasmids which provide a convenient source for the PLNRBS cassette containing a restriction site suitable for insertion of the cassette immediately upstream from an ATG are described. Other plasmids can easily be constructed by moving the cassette to any other host plasmids containing the proper sites. Such sites may be directly inserted into a host plasmid at the location of identical or compatible restriction sites normally available in the host plasmid, or at newly constructed compatible sites which can be engineered by digestion of the host plasmid at available sites and insertion of suitable commercially available linkers. Additional plasmids are described which provide the P NRBS~ ATG cassette, i.e., the cassette contains the ATG start codon operably linked to the ribosome binding site. Other plasmids suitable for cloning this cassette can be constructed using methods known in the art. C. Methods Employed Both cloning and expression vectors for desired sequences were constructed using the below described commonly employed restriction and ligation procedures. Additional plasmids, analogous to those illustrated, can also be constructed using these methods, which are well known in the art, by utilizing alternative replicons, vector fragments, control sequences, coding sequences, polylinkers, and expression cassettes. In general, the quantity of DNA available can be increased by cloning the desired fragments, i.e., inserting into a suitable cloning vehicle, such as pBR322, transforming and replicating in E. coli, and, optionally, further enhancing through chloramphenicol amplification or by phage replication. For expression, the desired fragments can then be removed from the cloning .vectors or phage and ligated to suitable control sequences compatible wi ' th the host intended to be employed in the expression of the gene. Such hosts are then transformed with these expression vectors arid cultured under conditions which favor stabilization of the plasmid and the safe production of a desired protein fragments. Such conditions might include repression of the controlling promoter until most of log phase has been completed, and then alteration of conditions so as to favor the synthesis of the peptide. Cl Control Sequences and Hosts As the marker cassette and fusion flag of the invention are intended to be utilized in a variety of hosts, it is incorporated into expression vectors containing promoters and any other required control sequences suitable for the appropriate host cell. Vectors compatible with procaryotes, and suitable for transformation of such vectors into these host cells are described with respect to use of E. coli K12 strain, MM294 or, in some instances, a lambda lysogen of E. coli strain MC1000 and are set forth in detail. However, other microbial strains may also be used, such as bacilli, for example Bacillus subtilis, various species of Pseudomonas, or other bacterial strains. In such procaryotic systems, plasmid vectors which contain replication sites and control sequences derived from a species compatible with the host are used. For example, E. coli is typically transformed using derivatives of pBR322, a plasmid derived from an E. coli species by Bolivar, et al. Gene (1977) zSδ. pBR322 contains genes for ampicillin and tetracycline resistance, and thus provides additional markers which can be either retained or destroyed in constructing the desired vector. Commonly used procaryotic control .sequences which are defined herein to include transcription initiation, optionally with an operator, along with ribosome binding site sequences, include such commonly used promoters as the beta-lactamase (penicillinase) and lactose (lac) promoter systems (Chang, et al. Nature (1977) 198:1056 and the tryptophan (trp) promoter system (Goeddel, et al, Nucleic Acids Res (1980) 8.:4057 and the lambda derived P L promoter and N-gene ribosome binding site (Shimatake, et al. Nature (1981) ' 292:128, which has been made useful as a portable control cassette, as set forth in copending Application Serial No. 578,133, filed February 8, 1984, and assigned to the same assignee. However, any available promoter system compatible with procaryotes can be used. In addition to bacteria, eucaryotic microbes, such as yeast, may also be used as hosts. Laboratory strains of Saccharomyces cerevisiae. Baker's yeast, are most used although a number of other strains are commonly available. While vectors employing the 2 micron origin of replication are illustrated. Broach, J. R., Meth Enz (1983) 101:307, other plasmid vectors suitable for yeast expression are known (see, for example, Stinchcomb, et al. Nature (1979) ^2:39, Tschempe, et al. Gene (1980) 1 :157 and Clarke, L., et al, Meth Enz (1983) 101:300). Control sequences for yeast vectors include promoters for the synthesis of glycolytic enzymes (Hess, et al, J Adv Enzyme Reg (1968) χ:149; Holland, et al. Biochemistry (1978) 17:4900). Additional promoters known in the art include the promoter for 3-ρhosphoglycerate kinase (Hitzeman, et al, J Biol Chem (1980) 255:2073), and those for other glycolytic enzymes, such as glyceraldehyde-3- phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate rautase,. pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase. Other promoters, which have the additional advantage of transcription controlled by growth ' conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, and enzymes responsible for maltose and galactose utilization (Holland, ibid). It is also believed terminator sequences are desirable at the 3' end of the coding sequences. Such terminators are found in the 3' untranslated region following the coding sequences in yeast-derived genes. In the constructions below, the 3' untranslated region of the enolasel gene is used; alternate sources for such sequences are available in the art. Many of the vectors illustrated contain control sequences derived from the enolase gene containing plasmid peno46 (Holland, M. J., et al, J Biol Chem (1981) 256:1385) or the LEU2 gene obtained from pYE13 (Broach, J., et al. Gene (1979) .8:121), however any vector containing a yeast compatible promoter, origin of replication and other control sequences is suitable. It is also, of course, possible to express genes encoding polypeptides in eucaryotic host cell cultures derived from multicellular organisms. See, for example. Tissue Cultures, Academic Press, Cruz and Patterson, editors (1973). Useful host cell lines include VERO and HeLa cells, and Chinese hamster ovary (CHO) cells. Expression vectors for such cells ordinarily include promoters and control sequences compatible with mammalian cells such as, for example, the commonly used early and late promoters from Simian Virus 40 (SV 40) (Fiers, et al. Nature (1978) 27_3:113), or other viral promoters such as those derived from polyoma, Adenovirus 2, bovine papiloma virus, or avian sarcoma viruses. Origins of replication may be obtained, if needed, from similar sources. However, integration into the chromosome is a common mechanism for DNA replication in eucaryotes. Plant cells are also now available as hosts, and control sequences compatible with plant cells such as the nopaline synthetase promoter and polyadenylation signal sequences (Depicker, A., et al, J Mol Appl Gen (1982) 1 : 561) are available. P C.2 Transformations Depending on the host cell used, transformation is done using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described by Cohen, S. N., proc Natl Acad Sci (USA) (1972) 6^:2110 is used for procaryotes or other cells which contain substantial cell wall barriers. Infection with Agrobacterium tumefaciens (Shaw, C. H., et al Gene (1983) .23.:315) is used for certain plant cells. For mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology (1978) 5_2:546 is preferred. Transformations into yeast were carried out according to the method of Van Solingen, P., et al, J Bact (1977) 130:946 and Hsiao', C. L., et al, Proc Natl Acad Sci (USA) (1979) 7J5:3829. Briefly, yeast cultures grown to raid-log phase in YEPD rich medium (yeast extract, peptone and 4% glucose) were washed and protoplasted with zymolyase 5000 (Miles Laboratory) in sorbitol phosphate buffer. Protoplasts were washed, allowed to stand at room temperature for one hour in 67% YEPD containing 1 M sorbitol, then pelleted and suspended in Tris-sorbitol-calcium chloride buffer to 2 x 109 protoplasts/ml. protoplasts were mixed with 5- 10 μg of DNA for transformation in a 100 μl reaction mix, then 1 ml of 44% PEG was added and the mixture allowed to stand for 40 minutes at room temperature. C.3 Selection for G418 Resistance For direct G418 resistance selection, dilutions of the transformation mixture were pipetted onto nutrient agar plates appropriate to the host (YEPD containing 1 M sorbitol and 3% agar for yeast) and overlayed with 13 ml of the same nutrient agar (50°C). After 2-6 hours incubating at 30°C the plates are overlaye.d with 4 ml of similar medium (YEPD (2% agar) for yeast) and G418. The concentration of G418 for the total volume of agar on the plate (30 ml) was 100 to 250 μg/ml. C.4 Vector Construction Construction of suitable vectors containing the desired coding and control sequences employs standard ligation and restriction techniques which are well understood in the art. Isolated plasmids, DNA sequences, or synthesized oligonucleotides are cleaved, tailored, and religated in the form desired. Site specific DNA cleavage is performed by treating with the suitable restriction enzyme (or enzymes) under conditions which are generally understood in the art, and the particulars of which are specified by the manufacturer of these commercially available restriction enzymes. See, e.g., New England Biolabs, Product Catalog. In general, about 1 μg of plasmid or DNA sequence is cleaved by one unit of enzyme in about 20 μl of buffer solution; in the examples herein, typically, an excess of restriction enzyme is used to insure complete digestion of the DNA substrate. Incubation times of about one hour to two hours at about 37°C are workable, although variations can be tolerated. After each incubation, protein is removed by extraction with phenol/chloroform, and may be followed by ether extraction, and the nucleic acid recovered from aqueous fractions by precipitation with ethanol followed by running over a Sephadex G-50 spin column. If desired, size separation of the cleaved fragments may be performed by polyacrylamide gel or agarose gel electrophoresis using standard techniques. A general description of size separations is found in Methods in Enzymology (1980) J55_:499-560. Restriction cleaved fragments may be blunt ended by treating with the large fragment of E. coli DNA polymerase I (Rlenow) in the presence of the four deoxy- nucleotide triphosphates (dNTPs) using incubation times of about 15 to 25 min at 20 to 25°C in 50 mM Tris pH 7.6, 50 mM NaCl, 6 mM MgCl2' 6 M D and 5 "1° *-* M dNTPs. The Rlenow fragment fills in at 5' sticky ends but chews back protruding 3' single strands, even though the four dNTPs are present. If desired, selective repair can be performed by supplying only one of the, or selected, dNTPs within the limitations dictated by the nature of the sticky ends. After treatment with Rlenow, the mixture is extracted with phenol/chloroform and ethanol precipitated followed by running over a Sephadex G-50 spin column-. Treatment under appropriate conditions with 51 nuclease results in hydrolysis of any single-stranded portion. Synthetic oligonucleotides are prepared by the triester method of Matteucci, et al (J Am Chem Soc (1981) 103:3185-3191). Rinasing of single strands prior to annealing or for labeling is achieved using an excess, e.g., approximately 10 units of polynucleotide kinase to 1 nmole substrate in the presence of 50 mM Tris, pH 7.6, 10 mM MgCl 2 , 5 mM dithiothreitol, 1-2 mM ATP, 1.7 pmoles γ 32 p A (2.9 mCi/mmole), 0.1 mM .spermidine, 0.1 mM EDTA. Ligations are performed in 15-30 1 volumes under the the following standard conditins and temperatures: 20 mM Tris-Cl pH 7.5, 10 mM MgCl 2 , 10 mM DTT, 33 μg/ml BSA, 10 mM-50 mM NaCl, and either 40 μM ATP, 0.01-0.02 (Weiss) units T4 DNA ligase at 0°C (for "sticky end" ligation) or 1 mM ATP, 0.3-0.6 (Weiss) units T4 DNA ligase at 14°C (for "blunt end" ligation). Inter- molecular "sticky end" ligations are usually performed at 33-100 μg/ml total DNA concentrations (5-100 nM total end concentration). Intermolecular blunt end ligations (usually employing a 10-30 fold molar excess of linkers) are performed at 1 μM total ends concentration. In vector construction employing "vector fragments," the vector fragment is commonly treated with bacterial alkaline phosphatase (BAP) in order to remove the 5' phosphate and prevent religation of the vector. BAP digestions are conducted at pH 8 in approximately 150 mM Tris, in the presence of Na + and Mg + 2 using about 1 unit of BAP per μg of vector at 60° for about one hour. In order to recover the nucleic acid fragments, the preparation is extracted with phenol/chloroform and ethanol precipitated and desalted by application to a Sephadex G-50 spin column. Alternatively, religation can be prevented in vectors which have been double digested by additional restriction enzyme digestion of the unwanted fragments. C.5 Verification of Construction In the constructions set forth below, correct ligations for plasmid construction are confirmed by transforming E. coli strain MM294 obtained from E. coli Genetic Stock Center, CGSC #6135, 'or other suitable host with the ligation mixture. Successful transformants are selected by ampicillin, tetracycline or other antibiotic resistance or using other markers depending on the mode of plasmid construction, as is understood in the art. Plasmids from the transformants are then prepared according to the method of Clewell, D. B., et al, Proc Natl Acad Sci (USA) (1969) ^2:1159, following chloramphenicol amplification (Clewell, D. B., J Bacteriol (1972) 110:667). The isolated DNA is analyzed by restriction and/or sequenced by the dideoxy method of Sanger, F. et al, Proc Natl Acad Sci (USA) (1977) 7_4:5463 as further desribed by Messing, et al, Nucleic Acids Res (1981) 9.:309, or by the method of Maxam, et al, Methods in Enzymology (1980) 65:499. C.6 Hosts Host strains used in cloning and expression herein are as follows: For cloning and sequencing, and for expression of construction under control of most bacterial promoters, E. coli strain MM294 (supra), Talmadge, R., et al. Gene (1980) 12,:235; Meselson, M., ' et al. Nature (1968) 217:1110, was used as the host. However, when expression is under control of the procaryotic P L promoter and NRBS tne E. coli strain MC1000 Lambda N7 53CI857SUSP-30 as an expression host was used (ATCC 39531, deposited December 21, 1983). This strain is hereinafter referred to as MC10Q0-39531.- This strain contains a lambda prophage which codes for a temperature sensitive Cl repressor, which at the permissive temperature (30-32°C) is active. At the non- permissive temperature (36-44°C), the repressor is inactive and transcription from the P***. promoter can proceed. It is further characteristic of this strain that at elevated temperatures the prophage fails to induce. Expression in yeast employed a laboratory strain of S. cerevisiae designated S173-6B, which is LEU2~, URA3", TRP1", HIS4-. This strain is obtainable from Professor Midime Holland, university of California, Davis. Industrial yeast S. cerevisiae strains used included Red Star distillers activated dry yeast (red Star Yeast Co., Oakland, CA); strain GB4722 obtainable from Dr. Anthony Rose, University of Bath, Bath, England; and CBS 6508, Centraal bureau Voor Schimmel cultures, Netherlands. C.7 Verification of DNA Uptake Transformations using yeast hosts were tested for uptake and replication of the desired sequences by DNA isolation and Southern Blot. DNA is isolated by the method of Sherman, F., et al. Methods in Yeast Genetics (1979), Cold Spring Harbor Laboratory. Briefly, after growth to late log phase in the appropriate selective medium (e.g., YEPD and 150 μg/ml G418), cells were washed and protoplasted with zymolyase 5000 (Miles Laboratory) in 1 M sorbitol, 20 mM EDTA. The protoplasts were then pelleted and suspended in 0.15 M NaCl, 0.1 M EDTA, predigested pronase and SDS added and the protoplasts incubated one to three hours at 37°C. The mixture was heated to 70°C for 15 minutes, put on ice, and potassium acetate added to 0.5 M. After 30 minutes on ice, the mixture was centrifuged and the resulting -supernatant treated with RNase and extracted with chloroform and isoamyl alcohol (24:1). The aqueous phase was centrifuged and the resulting supernatant ethanol precipitated, the precipitate was washed and resuspended, and the DNA precipitated with isopropanol. Southern Blot analysis was .done according to the method of Southern, J Mol Biol (1975) 98:503. Briefly, the isolated DNA was digested to completion with one or more restriction endonucleases, and run on agarose gels with molecular weight markers. DNA fragments were depurinated, ύi situ, with 0.075 M HC1, denatured in 0.5 M NaOH, 1.5 M NaCl, and neutralized in 1 M Tris-Cl pH 7.4, 3 M NaCl. The DNA on the gels was transferred to nitrocellulose filters via diffusion blotting in 20 x SSC overnight. The filters were then baked at 80°C in a vacuum oven for two hours. Before hybridization with probe, the nitro- cellulose filters were prehybridized. for 3 hours to over¬ night at 42°C in 50% formamide, 5 x SSC, 1/20 P/Pi (P/Pi is 0.05 M sodium pyrophosphate, 0.5 M sodium phosphate, monobasic, 0.5 M sodium phosphate dibasic), 0.1% SDS, 5 x Denhardt's (Denhardt's is 0.02% BSA, 0.02% Ficoll, 0.02% PVP), and 200 μg/ml sheared denatured carrier DNA. The filters were hybridized with 10-*-- cpm of (usually) 32p-ι a belled, nick-translated DNA probe in a solution of 50% formamide, 5 x SSC, 1/20 P/Pi, 0.1% SDS, 2 x Denhardt's, and 100 μg/ml sheared denatured carrier DNA at 42°C for 18-24 hours. The hybridized filters were washed three times- in 2 x SSC, 0.1% SDS at room temperature, dried and exposed to x-ray film. D. Detailed Description of Preferred Embodiments D.l Construction of Vector.s Containing Modified Truncated Ran Gene Under Trp Control - pFC19 and pFC19* The construction of pFC19 which contains mtAPH-I under trp control, is illustrated in Figure 2. E. coli R12 strain MM294 harboring plasmid pFC19 was deposited with the ATCC on December 22, 1983, and designated ATCC No. 39551. As shown in Figure 2, plasmid pFC19 is a ligation product of 5' PstI/blunt-3' DNA fragment containing the trp promoter and the N-terminal V2-10 APH-I coding sequence from plasmid MCR 4.1 and a mutated, 5'-blunt/PstI-3 * DNA fragment from plasmid pFC15 containing a modified C-terminal APH-I sequence. The pFC15 derived fragment in pFC*19 contains the majority.of the coding sequence for Ran gene but with a site specific mutations which destroys the Hindlll site that is present in the coding sequence, but retaining the meaning of the. codons. Both plasmid MCR4.1 and pFC15 were derived from pNG56, a plasmid containing the entire Ran gene coding sequence. The Ran coding sequence in pNG56 was shown to have a hol site at codons 10/11, it can thus be used to furnish the C-terminal codons 11-271 of APH-I by suitable digestion. pFC15 was derived from pNG56 by site specific mutagenesis, and contains a modification at codons 184/185 of the native sequence. Construction of pNG56 Plasmid pNG56 is a derivative of pNG20 (Grindley, N. D. F., et al, Proc Natl Acad Sci (USA) (1980) 77:7176). pNG20 encodes only the carboxy-terminal portion and downstream inverted repeat of the 3 kb sequence of APH-I from Tn601 disclosed by Oka, A., et a1 ' J Mol Biol (198.1) L47:217 (i.e., nucleotides 1701-3094 of the Oka sequences) and. thus fails to confer resistance to kanamycin. ρNG56 contains the entire Ran gene coding sequence but lacks, as does pNG20, the approximately 1.04 kb 5' (upstream) inverted repeat, present in Tn 601. To obtain pNG56, pNG20 was treated with Clal (which cuts uniquely upstream of the Tn 601 sequence) and with Hindlll (which cuts at codons 184/185 of the coding sequence). The desired control and N-terminal coding sequences were added by isolating the appropriate fragments resulting from Taql/Xhol and Xhol/Hindlll digestion of ρNG23, (Grindley, N. D. F., et al, (supra)) and performing a 3-way ligation of these two fragments with vector (Clal and- TaqI sticky ends are compatible). The ligation mixture was transformed into MM294 selecting for Amp R , Ran R and correct construction confirmed using standard methods. Construction of pFC15 PNG56 was linearized with Hindlll, and mutated with sodium bisulfite using the procedure of Shortle, D., et al, Proc Natl Acad Sci (USA) (1978) 75_:2170. After removal of the bisulfite, the mutagenized DNA was ligated (redigested with Hindlll), and used to transform E. coli R12 strain MM294. Ran R transformants were screened for plasmids which had lost a Hindlll recognition site, and the successful plasmid constructions retransformed into E. coli MM294 for purification. Ran R transformants were ! again selected. The correct construction was verified by restriction enzyme analysis and sequencing. Codons 184/185 were verified to have been changed from AAG CTT to AAA CTT Lys Leu Lys Leu Construction of MCR 4.1 MCR 4.1 which was used to provide the trp promoter sequence and the truncated front end of the Ran gene was constructed from pNG56 and pDG141 as shown in Figure 1 as follows: pNG56 was digested to completion with Xhol, repaired with Poll Rlenow fragment in the presence of all four dNTPs, and digested with EcoRI. The large approximately 5 kb fragment was isolated. It contains the coding sequence for all but the first ten codons of APH-I, blunt ended so as to be in 0 reading frame with an upstream sequence. pDG141 harbors the trp promoter operably linked to an ATG start codon, followed by a SacI site. It was deposited with the ATCC January 24, 1984, and has accession number 39588. pDG141 was digested with SacI, treated with Poll as above, and digested with EcoRI. The small 116 bp promoter/ribosome binding site and ATG start codon fragment, which is blunt ended so as to be in 0 reading frame with a downstream sequence, was purifed by acrylamide gel electrophoresis and electroelution. The pNG56 vector fragment and the promoter containing pDG141-derived fragment were ligated at about 200 μg/ml (1:1 molar ratio) under "sticky end" conditions, diluted fourfold, and the DNA fragments ligated under blunt-end conditions. The ligation mixture was used to transform E. coli MM294 and transformants selected for Amp R (50 g/ml) and screened with increasing concentrations of kanamycin (5, 10, and 15 μg/ml). Plasmid DNA was isolated from Amp R Ran R (more than 10 μg/ml) and analyzed by restriction enzyme digestion and DNA sequence analysis. A successful construction, which was designated MCR4.1, yielded a unique Hpal DNA fragment, a 530 bp Hindlll DNA fragment, and the expected altered Rsal digestion pattern. Completion of pFC19 pFC15 was then itself mutagenized using the same technique following digestion with Xmal. The Xmal digested, mutagenized fragments from pFC15 were repaired with E. coli DNA polymerase I (Poll), Rlenow fragment, in the presence of dCTP, dGTP, dATP, and then the flush ended DNA fragments digested with PstI and concentrated. To prepare the MCR4.1 fragment, pMCR4.1 was digested with Xmal, treated with SI nuclease under mild conditions (1 μl Sl/150 μl reaction at 20 β C, 20 min), and the fragments treated with PstI and concentrated. The pFC15 and MCR 4.1 fragments were. ligated at a 1:1 molar ratio using 0.62 mole ends for 5 hrs at 4°C using 40 M ATP and then overnight at 14°C using 1 mM ATP. The ligation mixture was digested with Xhol to inactivate the Ran promoter fragment of pFC15 and used to transform MM294. Colonies were selected in medium containing ampicillin (50 μg/ml). The Amp R enriched transformed population was diluted and grown in medium containing Amp (50 μg/ml) and Ran (20 μg/ml) and plasmid DNA purified from a Amρ R Ran R transformants. The plasmid preparation was digested with Smal to eliminate non- mutants and retransformed into E. coli strain MM294. Plasmid DNA was isolated from Ran R Amp R colonies and the correct construction confirmed by restriction analysis and DNA sequencing. The desired construct was designated PFC19. In ρFC19, the Xmal/Smal site at codons 93/94 of the V2-10 tAPH-I sequence had been mutagenized so that codons 93/94 were altered from CCC GGG to CCT GGG Pro Gly Pro Gly Using the procedures set forth above, but substituting for MCR 4.1, MCR 1.4, which was prepared as described in D.l.b.l, pFC19* is prepared. pFC19* is identical in every way to pFC19, except that the mtAPH-I has a 2-9 deletion rather than a 2-10 deletion. MCR 1.4 is similar to MCR 4.1 except that it effectively contains a deletion of codons 2-9 rather than of codons 2-10. Codon 10 is supplied by pDG142, a plasmid similar to PDG141 except that it has a Sau3A site immediately downstream of the ATG and a succeeding, in frame, TGT cys codon. Thus, plasmid MCR 1.4 was obtained using a procedure similar to that set forth in above, but substituting for the 116 bp promoter/RBS/ATG fragment from pDG141, the isolated 119 bp promoter/RBS/ATG TGT fragment obtained by digesting pDG142 with Sau3A, treating with SI nuclease, and digesting with EcoRI. Plasmid MCR 1.4 was verified by restriction enzyme analysis and DNA sequencing to be precisely identical to plasmid MCR 4.1 except for the additional 3 bp TGT sequence following the start codon. Thus, MCR 1.4 may be used in precisely the same manner as was MCR 4.1 to obtain plasmids encoding a V2-9 APH-I protein. D.2 Construction of mtAPH-I Vectors with 5' Polylinker Sequences - pDG144 and pFC2Q PDG144 contains the coding sequence for the modified truncated Ran gene 2-10, immediately preceded by a linker fragment containing EcoRI, Smal, BamHI, and Hindlll restriction sites; in pFC20, this linker is also preceded by a duplicated lac operator, an inverted repeat of this linker, and the trp promoter. Both contain, distal to the 3' translation termination codon, convenient StuI, Haell, BssHII, Mstl and PvuII sites. pDG144 was constructed from pFC19 in several steps through pFC20 as an intermediate (see Figure 4). pDG144 was deposited with the ATCC on January 13, 1984, ATCC NO. 39579. Construction of pFC20 pFC19 was first digested with Hpal to inactivate the trp promoter, and then with PstI and Hindlll. pFCll (see below) was digested with PstI and Hindlll to liberate the trp promoter and desired lac operator/linker fragment. These fragments were ligated under sticky-end conditions (3:1 molar ratio). The ligated DNA was digested with SacI to inactivate unwanted ligation products, and the mixture used to transform E. coli MM294. Successful transformants were selected for Amp R , Lac0 + and Ran R , and plasmid DNA isolated. The correct construction of pFC20 was confirmed by restriction analysis. pFC20, as shown in Figure 4, contains the desired linker/lac operator preceding the mtAPH-I 5' Hindlll site, which is downstream from the trp promoter. pFCll, used as the source of the polylinker/ lacO sequences in pFC20, and ultimately as a source of the polylinker in pDG144, was constructed from pDG141 (supra) in two steps, the second of which is shown in figure 3. PDG141 was first modified to convert a Clal site at the 3' end of the trp promoter to a BamHI site by the conventional procedure, i.e., treatment of pDG141 with Clal, blunt ending with Rlenow, and blunt-end ligation with a commercial BamHI linker. The resulting ligation mixture was used to transform MM294 to Amp R and the presence of a BamHI site verified in the desired pFClO. pFCIO (Fig 3) was digested with BamHI and ligated with BamHI digested pSYClll, (a 4.4 kb vector which had, in turn, been prepared by insertion of the desired 72 bp fragment into the BamHI site of pBR322; [(This 72 bp fragment has the sequence: BamHI, Smal, EcoRI, lacO, EcoRI, lacO, EcoRI, Smal, BamHI.)]. The ligation mixture was digested with PvuII and used to transform MM294 to Amp R , Lac0 + and screened for TetS. The correct construction of pFCll was confirmed by restriction enzyme analysis. Construction of pDG144 To obtain pDG144, pFC20 was treated as shown in Figure 4. The trp promoter and lac operators were removed from pFC20 by digesting to completion with EcoRI, religating, and transforming MM294 to lacO" RanS. The . correct*construction, pDG144, contains the 22 bp polylinker bearing EcoRI, Smal, and BamHI sites immediately upstream of the 5' Hindlll site of mtAPH-I. Digestion of pDG144 with Hindlll and, respectively, StuI (when cloned in dcm~hosts) Haell, MstI or PvuII yields DNA fragments containing the entire coding sequence of the V2-10 Ran gene of 1.03, 1.08, 1.15, or 1.21kb. In these fragments, the ATG start codon is proximal to the 5' Hindlll end. Using the procedures set forth above, but substituting for pFC19, pFC19*, the corresponding plasmids containing the mtAPH-I (V2-9) coding sequence preceded by polylinker sequences,. pFC20* and pDG144* are prepared. D.3 Vectors Containing mtAPH-1 with Eucaryotic Control Sequences PDG148 (SV40 Control) pDG148, diagrammed in Figure 7, contains the truncated 2-10 Ran gene under control of the SV40 promoter. This plasmid is illustrative of vectors suitable for expression of the Ran gene in eucaryotic cells and as a host plasmid for eucaryotic foreign gene expression providing mtAPH-I as a dominant selectable marker. It is also usable as a host plasmid providing the mtAPH-I C-terminal sequences of the fusion flag. PDG148 will replicate autonomously both in procaryotic (e.g., E. coli) and in eucaryotic cells (e.g., yeast and certain mammalian cell line) hosts. pDG148 was deposited with ATCC on December 22, 1983, and was given accession number 20695. The sequences in pDG148 (with reference to ' Figure 7) are as follows: 1. The 1.21kb fragment comprising the first 1.21 kb of pDG148 is the Hindlll/PvuII modified truncated Ran gene cassette from pDG144. This sequence, as stated above, has been mutated at codons 93/94 (of the truncated gene) to eliminate the Xmal/Smal recognition site and at codons 175/176 to destroy the Hindlll recognition site while retaining the same amino acid sequence in the encoded protein. 2. The SV40 viral promoter sequence containing the SV40 origin of replication, early viral promoter and transcriptional enhancer, is obtained by digesting isolated SV40 DNA with Hindlll and PvuII and ligating the blunt-ended PvuII end to a BamHI linker obtained from New England Biolabs. This occupies coordinates 1.21- 1.56. 3. Coordinates 1.56 kb to 1.83 kb are a 276 bp DNA fragment from pBR322 obtained by double digestion with BamHI and Sail and isolation of the 276 bp fragment. 4. The LEU2 gene from yeast occupies coordinates 1.83 kb-4.05 kb. This is derived from pYE13 (Broach, J., et al, Gene (1979) 8 ^ :121) by double digestion of this plasmid- with Xhol/Sall. 5. A yeast replication origin derived from the yeast 2 micron plasmid occupies coordinates 4.05 kb- 7.76 kb. It is obtained by digestion of pDB248 (Beach, D., et al. Nature (1981) 290:140) with EcoRI(repair)/ Sail and isolation of the 3.7 kb DNA fragment containing the replicon. The existence of the appropriate Sail site was not deducible from the disclosure of Beach. However, pDB248 was shown to contain a Sail site about 50 bp downstream fr.ora the indicated LEU2 region/2μ PstI tailing site as set forth in the Beach reference. 6. Finally, this plasmid is capable of replication in E. coli and of conferring Amp resistance . by inclusion of a 2145 bp DNA fragment obtained from pBR322 by double digestion with Tthllll(repair) and EcoRI. It occupies coordinates 7.76kb-9.9 kb of the 9.9 kb pDG148. PDG149 (Enolase Control) pDG149, diagrammed in Figure 7, is similar to PDG148 except that the truncated Ran gene (V2-10) is under the control of the enolase promoter and terminator rather than the SV40 promoter. The plasmid retains the yeast replicative sequences, the LEU2 gene, and the Amp R* and E. coli origin of replication derived from pBR322. PDG149 was deposited with ATCC on December 22, 1983, and given accession number 20694. The segments of pDG149 are as follows: 1. Coordinates 0-1.54 kb contain 3' untranslated ENOl yeast gene terminator sequences and are derived from a HindIII(repaired)/EcoRI digest of peno46 (Holland, M. J., et al, J Biol Chem (1981) 256:1385). The resulting EcoRI site is at coordinate 0, and the blunt-end segment of the ENOl fragment is ligated to the modified truncated Ran gene described below. 2. Coordinates 1.54-2.75 kb contain the truncated Ran gene modifed as set forth in connection with pDG148 above and also obtained from ρDG144 digested with Hindlll and PvuII. The PvuII site at the 3' end of the gene is ligated to the Hindlll, repaired, blunt end of the enolase terminator thus leaving a unique Hindlll site (5' to mtAPH-I) for subsequent ligation. 3. The enolase I promoter which is contained in the coordinates 2.75-5.80 kb was obtained from two intermediate derivatives of peno46 (Holland, M. J., et al, supra). The first intermediate was obtained by digestion with Hindlll, limited treatment with E. coli exonulcease III, SI nuclease and insertion of a Sail linker obtained from New England Biolabs. The resultant intermediate vector was treated with Sail, repaired with Rlenow, and ligated with a Hindlll linker obtained from New England Biolabs. This second modification placed a Hindlll site preceding the ATG initiation codon for the enolase I protein. This second intermediate derivative plasmid was double digested with Xmal and Hindlll to provide the 3.05 kb fragment which contains 1.76 kb of yeast DNA and also contains 1.29 kb of ColEl plasmid DNA ' encoding a portion of the colicin El protein. 4. Coordinates 5.80-5.91 kb contain the 112 bp trp control DNA fragment which was obtained by double digestion of pFCll (above) with EcoRI, repair with Rlenow, followed by digestion with Xmal and isolation of the 112 bp fragment having EcoRI (blunt) at the 5' coordinate (5.91 kb) and Xmal at the 3' coordinate (5.8 kb). 5. A 90 bp linking segment which comprises the DNA fragment between the Sphl(repair) and Sail recognition sites of pBR322 occupies- coordinates 5.9-6.0. 6. The LEU2 gene derived from yeast as a Xhol/Sall fragment occupies coordinates 6.0-8.21. This fragment was obtained in the same manner as that used to construct pDG148. 7. The 3.7 kb DNA fragment containing the 2 micron origin of replication for yeast was derived from pDB248 as described for pDG148 and occupies coordinates 8.21 to 11.93. 8. The Amp R gene and E. -coli replication . origin occupying coordinates 11.93-14.07 kb were derived from pBR322 as a TthlllI(repair)/EcoRI fragment as described above. PDG150 (Enolase Control) pDG150 was derived from pDG149 by deleting extraneous sequences of bacterial origin upstream of the enolase promoter, i.e., the trp promoter and the Colicin El sequences brought along with the peno46-derived fragment. PDG149 was cut with Sail (complete) at the unique Sal site upstream of the trp promoter sequence, and then subjected to partial digestion with Xbal to obtain cleavage at the Xba site immediately 5' of the yeast derived enolase promoter. After repair with Rlenow and the four dNTPs, the mixture was ligated and used to transform E. coli MM294 to Amp . The transformants were screened for the desired 11.62 kb plasmid containing unique Xbal and Sail sites. (The Sail site is regenerated upon ligation, the Xbal site is not.) The correct construction was designated pDG150. D.4 Preparation of Vectors Suitable for Fusion Flag Construction - pDG151 PDG151 is a 11.12 kb plasmid analogous to the foregoing pDG14'8, pDG149 and pDG150, except that the modified truncated Ran gene is linked to additional procaryotic control systems comprising duplicated lac operators in front of the trp promoter of pDG149 and is preceded by a polylinker. The eucaryotic promoter sequences linked to mtAPH-I have been deleted. In PDG151, the ENOl control sequences intervening between the trp promoter and the V2-10 modified Ran gene om PDG149 are replaced by a 0.1-kb sequence containing, a duplicated lac operator flanked by a short inverted repeat polylinker, and expression of the mtAPH-I can thus be regulated by either tryptophan levels or lac repressor synthesis. This fragment was derived by HindlII/BamHI(partial) digestion of pFC20 (above). The sequences of pDG151 are outlined in Figure 7, and consists of the following: 1. Coordinates 0-1.54 are the 1.54 kb Hindlll/EcoRI 3' untranslated terminator sequences of the Enol gene derived from pEno46 (Holland, et al, supra) and are identical with the sequences in the corresponding coordinates in pDG149. 2. Coordinates 1.54-2.75 contain the truncated Ran gene modified as noted above. This is the same Hindlll/PvuII digest of pDG144 described in connection with the corresponding sequences in pDG149, and which corresponds to the sequence occupied by coordinates 0- 1.21 in pDG148. 3. Coordinates 2.75-2.85 contain the duplicated lac operator sequence flanked by inverted polylinker repeats and was obtained from pFC20 (see Figure 4) by digestion with Hindlll and BamHI(partial). Correct BamHI digestion to give the fragment which includes the lacO duplication was -readily verifiable by- transforming hosts to Amp R and then screening for constitutive Lac z+ expression in E. coli R12 Strain MM294. The sequence immediately preceding the ATG start codon (at 2.75) is: 5' G AAT TCC CGG GGA TCC GGC GAT AAG CTT ATG EcoRI Xmal BamHI Hindlll 4. Coordinates 2.85-2.95 are the isolated 107 bp 5'-EcoRI(repaired)/BamHI-3' fragment from pFClO. This fragment contains the trp promoter- operator and is analogous to the 112 bp trp control fragment which occupies coordinates 5.80-5.91 kb in PDG149. 5. Coordinates 2.95-3.04 kb contain a 90 bp pBR322 segment between the SphI("repair) and Sail sites. 6. The LEU-2 gene from YEpl3 occupies coordinates 3.04-5.25. It was obtained as a Xhol/Sall digest from YEpl3 and is the same fragment as that which occupies similar locations in pDG148 and pDG149. 7. The 2 micron plasmid replicon in coordinates 5.25-8.97 is analogous to the pDB248 derived fragments in pDG148 and pDG149. 8. Coordinates 8.97-11.2 contain a TthlllKrepair)/EcoRI digest of pBR322 which supplies Amp R and an E. coli origin of replication. As pDG151 contains a polylinker preceding the ATG start of mtAPH-I, convenient restriction sites for creation of 5' fusion termini are available. D.5 Construction of Expression Vectors for LEU2mtAPH-I Fusions Four expression vectors were constructed which are effective in the production of LEU2 fusion proteins in yeast hosts. These fusion proteins contain the N-terminal sequences of β-isopropyl malate dehydrogenase in varying lengths, a few linker encoded amino acids, and the mtAPH-I sequence. All four such plasmids constructed were derived from pDG151 by cutting into the LEU2 sequence contained between coordinates 3.04 and 5.25 at various positions in the coding region and religating the N-terminal portion of the coding sequence into a polylinker which immediately precedes the mtAPH-I coding sequences in pDG151. These illustrative plasmids were designated pLR11.17, pLR51.57, pLR82.88, and pLR82.90. The designations refer to the coding sequences which make up the fusion (L (LEU) and R (Ran)) and to the nature of the fusion, the first number referring to the number of codons of the LEU2 sequence included, and the second number referring to the number of additional amino acids preceding the start codon for mtAPH-I. As described in paragraph D.4, the polylinker immediately preceding the mtAPH-I coding sequence contains four restriction sites: EcoRI, Smal, BamHI, and Hindlll. The LEU2 coding sequence contains a BstEII site which cuts at codons 12-14, a Clal site which cuts at codons 51-52, and a Rpnl site which cuts at codons 83-84. The following subparagraphs detail the use of these sites in the construction of exemplary fusion protein encoding plasmids. Construction of pLR11.17 pDG151 was digested to completion with BstEII, treated with SI nuclease, digested with PstI, and the 5.8 kb DNA fragment was purified following agarose gel electrophoresis. The BstEII LEU2 site is as shown: 11 12 13 14 Pro Gly Asp His CCA GGT GAC■ CAC BstEII . This 5.8 kb fragment thus provides the LEU2 promoter sequences and the first 11 codons of the LEU2 sequence and the first nucleotide of codon 12. To provide the mtAPH-I portion, the pDG151 was digested to completion with BamHI, treated with Rlenow in the presence of all four dNTPs, digested with PstI, and the 3.52 kb DNA fragment purified. This fragment provides the coding sequence for mtAPH-I, along with codons for 5 2/3 amino acids encoded by the polylinker, and also provides the enolase termination sequences. Equimolar mixtures of the above pDG151 fragments were ligated at a total DNA concentration of 60 μg/ml under sticky-end conditions for 12 hours and then under blunt-end conditions at a DNA concentration of 20 μg/ml. The ligation mixture was used to transform E. coli MM294 to Amp R , and the Amp R colonies screened for the presence of the desired 9.3 kb plasmid, which was expected to contain a unique regenerated BamHI site. Candidate plasmids were further screened by restriction enzyme analysis, and then by DNA sequencing using a pentadecamer primer 5' CAGCATCCATGTTGG-3' which is complementary to nucleotides 23-37 of the mtAPH-I coding sequence. The nucleotide sequence at the fusion was confirmed to be: 1 ... 11 12 13 14 15 16 17 18 19 ATG... CCA GGA TCC GGC GAT AAG CTT ATG TCG Met... Pro Gly Ser Gly Asp Lys Leu Met Ser BamHI Hindlll LEU2 * polylinker ψ—Ran Construction of pLR51.57 pDG151 was digested ' to completion with Clal, treated with Rlenow in the presence of dCTP and dGTP, digested with PstI, and the 5.92 kb DNA fragment was isolated. Clal cleaves the LEU2 coding sequence as shown: 50 51 52 53 Ala He Asp Ala GCT ATC GAT GCT Clal . This fragment thus provides, in addition to the LEU2 promoter, codons 1-51 of the LEU2 sequence along with the first nucleotide of codon 52. The 5.92 kb fragment containing the mtAPH-I codons and enolase terminator was prepared exactly as set forth in paragraph D.δ.a above. Equimolar amounts of these fragments were ligated and the ligation mixture used to transform E. coli MM294 to Amp R as described in paragraph D.6.a above. Amp R colonies were screened for the desired 9.44 kb plasmid containing the unique regenerated BamHI site. Candidate plasmids were further screened by restriction analysis. DNA sequencing using the same pentadecamer primer as above confirmed the sequence at the fusion of the correct construction, pLR51.57 to be: 1 ... 50 51 52 53 54 55 56 57 58 59 . . . ATG.. GCT ATC GGA TCC GGC GAT AAG CTT ATG TCG . . . Met.. Ala He Gly Ser Gly Asp Lys Leu Met Ser . . . BamHI Hindlll LEU2- = * - polylinker T* * !**** Kan Construction of pLR82.88 pDG151 was digested' to completion with Rpnl, digested with BamHI, and treated with Rlenow in the presence of all four dNTPs. Rpnl cleaves the LEU sequence as shown: 82 83 84 85 Trp Gly Thr Gly TGG GGT ACC GGT Rpnl • ( Thus, the resulting linear blunt-ended fragment contains at the Rpnl (blunt) end the LEU2 promoter along with the first 82 codons of the LEU2 gene, and an additional G from codon 83; the BamHI (blunt) end provides the codons for mtAPH-I, preceded by several polylinker codons, and followed by the enolase terminator. The fragments were ligated under blunt-end conditions at a total DNA concentration of 20 μg/ml to favor intramolecular blunt-end ligation, and the mixture used to transform MM294 to Amp R . Amp R colonies were screened for the presence of the desired 9.54 kb plasmid containing the unique regenerated BamHI site. Candidate plasmids were further mapped by restriction " analysis and finally by DNA sequencing. The relevant fusion sequences in pLR82.88 were confirmed to be: 1 ... 82 83 84 85 86 87 88 89 90 ATG... TGG GGA TCC GGC GAT AAG CTT ATG TCG Met... Trp Gly Ser Gly Asp Lys Leu Met Ser Construction of PLR82.9Q pDG151 was digested'to completion with Rpnl, blunt-ended with Rlenow in the presence of dGTP, digested with Bglll and the desired 6.88 kb DNA fragment 10 was purified. This fragment provides the LEU2 promoter, the first 82 LEU2 codons, and 1 nucleotide of codon 83. To obtain the Ran gene for fusion, pDG151 was digested to completion with EcoRI, treated with SI nuclease, digested with Bglll, and the desired 2.53 kb fragment purified. 15. This fragment provides 7-2/3 codons from the polylinker. The 2 foregoing fragments were ligated in equimolar ratio under sticky-end conditions (60 μg/ml total DNA), diluted to 10 μg/ml and ligated under blunt- end conditions to favor intramolecular ligation. The 20 ligation mixture was transformed into E. coli MM294 to Amp R and the colonies screened for the presence of the desired 9.4 kb plasmids containing an additional Apal recognition site. Plasmids were further mapped by restriction analysis and the correct construct, pLR82.90, 25 was confirmed by DNA sequencing as above, to contain the fusion sequence: 1 ... 82 83 84 85 86 87 88" 89 90 91 92 . . . ATG... TGG GCC__CGG GGA TCC GGC GAT AAG CTT ATG TCG ... Met... Trp Ala Arg Gly Ser Gly Asp Lys Leu Met Ser . .. . 0 Apal Smal BamHI Hindlll -LEU2- → - -polylinker- Kan- D.6 Construction of Plasmids Containing Enolase Fusions PER7.14 encodes inframe fusions of the first 7 codons of ENOl, 7 codons of polylinker, and the 262 mtAPH-I codons, all under the control of the enolase promoter and terminating sequences. The mtAPH-I codons and enolase terminator are derived from pDG151; the remaining codons and enolase promoter- are obtained from a derivative of pEno46. To obtain the derivative, ρEno46 was first modified by digesting with Hindlll, treating with E. coli exonucleaselll, SI nuclease, BAP and ligation in the presence of the self-complementary phosphorylated Sail octanucleotide 5 * -GGTCGACC-3' under blunt-end conditions. The ligation mixture was used to transform E. coli MM294 to Amp R , and Amp R colonies screened for the presence of a new Sail site. The modified plasmid, pEno46(I24) was confirmed by dideoxy sequencing to have inserted the Sail octanucleotide immediately after codon 7 in the Enol coding sequence. This Sail cleavage site is -1 in the Enol reading frame and encodes a Gly-Arg-Pro tripeptide. The desired sequences from pEno46(I24) were transferred to M13 phage to provide M13mp8::Eno46(I24). To do this, pEno46(I24) was digested with Sail and EcoRI, and the desired 745 bp ENOl promoter fragment purified. Bacteriophage M13mp8RF DNA was digested to completion with EcoRI and Sail and the above purified 745 bp fragment and the M13 vector were ligated (3:1 molar ratio), at 50 μg/ml total DNA concentration under sticky- end conditions. E. coli R12 strain WB373 (an M13- sensitive host) was transformed with 100 nanograms of the ligation mixture, and the plaques screened for the presence of the 745 bp insertion. The desired recombinant phage fuses 7 codons of the polylinker sequence from M13mp8 in frame to the first 7 codons of Enol provided by pEno46(l24). The reading frame encoded by the Hindlll site in this recombinant phage is identical (+1) with the reading frame encoded by the polylinker Hindlll site (+1) in pDGl51. Thus, this recombinant phage is a convenient source for the 760 bp EcoRI/HindlH fragment used to construct pER7.14. The recombinant phage, M13mp8Eno46(I24) RF DNA, was digested with EcoRI, repaired with Rlenow in the presence of dATP and TTP, digested with Hindlll, and the 760 bp ENOl promoter fragment purified. Plasmid PDG151 was digested to completion with Sail, repaired with Rlenow in the presence of all four dNTPs, and digested with Hindlll. The purified ENOl promoter and digested vector fragments were ligated in a 2:1 molar ratio under sticky-end conditions at 60 μg/ml total DNA, and the ligated fragments diluted to 20 μg/ml. and ligated under blunt-end conditions. The mixture was used to transform E. coli MM294 to Amp R on plates containing, x-gal, and white Amp R transformants were screened for the presence of the desired 11.6 kb plasmid. (Transformants containing plasmids which had deleted the 280 bp lac operator fragment preceding mtAPH-I would be expected to give white colonies.) Candidate plasmids were further mapped by restriction enzyme digestion and the resulting sequence at the fusion confirmed in pER7.14 to be: -EOl- -linker - kan- Met Ala Val Ser Lys Val Tyr Gly Arg Pro Ala Ala Lys Leu Met Ser ATG GCT' GTC TCT AAA QTΣ TAC GGT CGA CCT GCA GCC AAG CTT ATG TOG Sail PstI Hindlll D.7 Construction of pDG151::RSV; a Vector Having Alternative Control Sequences pDG151::RSV is a S. cerevisiae/E. coli shuttle vector using control sequences derived from Rous Sarcoma Virus, it is constructed from pDG151 by removing the sequences between coordinates 3.04 and 2.75 and replacing them with the RSV promoter sequences (religation at the ATG-preceding Hindlll site regenerates operable linkage of the promoter with the mtAPH-I codons). Plasmid pDG151 was digested to completion with Sail, treated with E. coli DNA polymerase I, Rlenow fragment, in the presence of all four dNTPs, and finally digested to completion with Hindlll. Plasmid pRSV-NeoI (see below) was digested to completion with Nrul and Hindlll. The digested DNA fragments were mixed (1:2.5 molar ratio) and ligated at 50 μg/ral (total DNA concentration) under sticky-end conditions. The ligated linear DNA fragments were diluted to 25 μg/ml and further ligated under blunt-end conditions to favor intramolecular circle formation. The ligated DNA was digested with PvuII (to inactivate undesired pRSV-NeoI ligation products) and 150 ng of the DNA used to transform E. coli R12 strain MM294 to ampicilin resistance. Non-constitutve Lac + colonies (absence of 280 bp Sall/Hindlll DNA fragment of pDG151) were screened for kanamycin resistance. Amp R Ran R candidate colonies were screened for the presence of the desired 11.24 kb plasmid containing the 400 bp Nrul/Hindlll DNA fragment encoding the Rous Sarcoma virus promoter. Plasmid pDG151::RSV (11.24 kb) released the diagnostic 1235 bp EcoRI fragment (fusion of 928 bp of LEU2 DNA to 307 bp of RSV DNA), regenerated the desired Sail recognition site (Sail repair, GTCGA/CGA, Nrul fusion) and generated the diagnostic Sall/EcoRI (307 bp) and NruI/EcoRI (150 bp) DNA fragments. Construction of pRSVNeoI Plasmid pRSVneo (5.73 kb, renamed here pRSVneolI to distinguish the APH-II coding sequence from the modified, truncated APH-I coding sequence of this invention) as been described (Gorman, C, et al, Science (1983) .:551-553). p SVneolI was modified to give pRSVNeoI by replacing the 1210 bp Hindlll/Pvull DNA fragment encoding the mtAPH-I coding sequence (from plasmid pFC20) for the 1352 bp Hindlll/Pvull region of pRSVneolI encoding the bacterial promoter and structural coding sequences for APH-II (Beck, E., et al. Gene (1982) 19:327). Plasmid pRSVneolI was digested to completion with PvuII and Hindlll Plasmid pFC20 was digested to completion wth PvuII and Hindlll. The digested DNA fragments were mixed (1:1 molar ratio) and ligated at 40 μg/ml (total DNA concentration) under sticky-end conditions. The ligated linear DNA fragments were diluted to 20 μ g/ml and further ligated under blunt-end conditions to favor intramolecular circle formation. E. coli R12 strain MM294 was transformed to Amp R with 150 ng of the ligated DNA and non-constitutive Lac + colonies (transformed with the pRSVneolI origin containing fragment rather than the pFC20 origin containing fragment) were screened for the presence of the desired 5.59 kb plasmid. Plasmid candidates were screened with Hindlll (unique site), PvuII (unique site), Hindlll/Pvull (4.3 and 1.21 kb DNA fragments), and EcoRl ' (3.04 and 2.55 kb DNA fragments). Plasmid DNA from one transformant, designated pRSVneoI (5.59 kb), encoded the mtAPH-I coding sequence substituted for the APH-II promoter and coding sequence. Additionally, plasmid pRSVneoI conferred a high level of kanamycin resistance to E. coli R12 strain MM294 (>10Q μg/ml). E. Expression of and Selection by Truncated Ran Gene E.l Expression in E. coli Figure 5 indicates that ' plasmid MCR 4.1 has lost codons V2-10 of the wild type APH-I protein (V2-10) yet confers a very high level of resistance to kanamycin (100% plating efficiency at 300 μg/ml drug) on minimal media. Similarly, plasmid MCR 1.4 has lost codons 2-9 of the wild type APH-I protein and confers a very high level of resistance to kanamycin. Thus the cysteine at position 10 in the wild-type sequence and amino acids 2 through 9 of the wild-type protein, sequence are not essential for activity. Figure 6 shows a portion of a series of two dimensional electrophoretic separations (O'Farrell, P. J., et al, J Biol Chem (1975) 250:4007) of extracts from E. coli R12 strain MM294 harboring no plasmid (Panel A), wild-type plasmid pNG56 (Panel B), plasmid MCR 1.4 (codon 2-9 deletion) (Panels C and D) or plasmid MCR 4.1 (codon 2-10 deletion) (Panels E and F). Cultures were grown in the absence (Panels A, C, E) or presence (Panels B, D, F) of tryptophan (100 μg/ml) and labeled with 35S-Methionine (10 μc/ml) for five minutes. Figure 6 demonstrates that plasmids MCR 4.1 and MCR 1.4 encode proteins of lower apparent molecular weight and altered apparent charge. Compare position of circled wild-type protein (Panel B) with arrows indicating new polypeptide chains synthesized by cells harboring plasmids MCR 1.4 and MCR 4.1. In addition. Figure 6 demonstrates that the synthesis of these new, altered polypeptides is regulated by the level of tryptophan in the medium (cf panels C and E with D and F, respectively) consistent with the truncated coding sequences of this mixture in operable linkage to the E. coli trp promoter. Furthermore, purified APH-I 2-10 comigrates with the new, major labeled spot indicated in panel E (not shown). Further, the altered Hindlll recognition site mutation encoded by plasmid pFC15 and the altered Xmal/Smal recognition site encoded by plasmid pFC19 do not change the high level of resistance conferred by these modified APH-I coding sequences. E.2 Use of mtAPH-I as a Dominant Selectable Marker in Eucaryotes The e ficacy of mtAPH-I as a selection tool for eucaryotic transformation, i.e., in lacY" hosts is shown by the results in Table 1. Table 1 Transformation Frequency Plasmid Promoter 100 μ g G418/ml 200 u g G418/ml PDG150 Enol 1.2 x 10 3 0.18 x 10 3 pLRH.17 LEU2 1.3 x 10 3 0.98 x 10 3 PDG148 SV40 early 0.5 x 10 3 0.12 x 10 3 pDG151::RSV Rous LTR 1.2 x 10 3 0.83 x 10 3 Plasmids encoding mtAPH operably linked to control sequences appropriate to eucaryotes were used to transform S. Cerevisiae S173-6B protoplasts as described; As shown in Table 1 transformation frequencies of the expected magnitude, were obtained. Frequencies are expressed as directly selected G418 R transformants/μg of plasmid DNA. The results of Table I ace also shown in Figure 8 which compares growth on G418 containing medium of both transformed and non-transformed S173-6B: (1) no plasmid; (2) pLR11.17; (3) pDGl48; (4) pDG150; (5) pDG151::RSV. The transformation frequencies selected by G418 were 2-4 fold higher than those obtained using LEU2 + selection. Figure 9 shows similar results obtained when the hosts were industrial yeast strains. S.cerevisiae strains 5121, C454, C464, three industrial yeast strains used for ethanol production or the baking of bread, Red Star, CBS6508, and GB4722, were transformed with plasmid pDG149 and the transformants directly selected for G418 R as described in UC.3. The plates on the left resulted from G418 R selection of protoplasts not treated with plasmid DNA. In contrast, the plates on the right resulted from G418 R selection of protoplasts treated with pDG149. The top panel is Red Star; the middle panel is CBS6508; the bottom panel is GB4722. Southern blots of DNA extracted from transformed yeast performed according to the procedure of HC.7, further confirmed the presence of the mtAPH-I coding sequence in the transformed hosts. E.3 Resistance Levels Obtained (Procaryotes/ Eucaryotes The level of G418 resistance conferred on yeast by plasmids containing eucaryotic control systems is even greater than the level of Ran R conferred on E. coli by plasmids containing the trp promoter or LEU2 promoter, both operable in E. coli. Table 2 shows the concentrations of anibiotic required to give a 50% plating efficiency for plasmid- containing cells. The column designated "E. coli" shows kanamycin resistance for plasmid-containing E. coli R12 strain MM294; the column designated "S. cerevisiae" shows G418 resistance for plasmid containing S. cerevisiae strain S173-6B. Table 2 Host Plasmid E. coli S. cerevisiae None < 5 μg/ml < 25 μg/ml PDG148 < 5 μg/ml 160 μg/ml PDG149 < 5 μg/ml > 1.0 mg/ml PDG150 < 5 μg/ml > 1.0 mg/ml pFC19 > 150 μg/ml N.D. PDG151: :RSV > 100 μg/ml 500 μg/ml pLRH.17 10 μg/ml > 1.0 mg/ml PLR51.57 > 300 μg/ml > 1.0 mg/ml PLR82.88 > 300 μg/ml > 1.0 mg/ml PLR82.90 > 300 μg/ml > 1.0 mg/ml The level of resistance can thus be used as an assay for the quantity of APH-I activity produced. PDG148, pDG150, pFC19, and pDG151::RSV are expression vectors for the mature mtAPH-I sequence under the control of respectively, SV40 (mammalian), ENOl (yeast), trp (E. coli) and RSV (mammalian) promoters. All of the fusions show high activity expression levels as compared to the mature protein. E.4. Fusion Protein Production in Eucaryotes Yeast transformed with vectors encoding the fusion proteins were analyzed to verify the production of the expected fused sequence by gel electrophoresis and by Western analysis. Figure 10 shows the production of the yeast enolase fusion, using mtAPH-I expression as a control.' Extracts of yeast strain S173-6B host cells ' without plasmid (Panel A); transformed with pDG150 (Panels B & C); and with pER7.14 (Panels D & E) were subjected to O'Farrell (O'Farrell, P. J., et al, J. Biol. Chem. (1975) 250:4007) two-dimensional electrophoresis following 35S methionine pulse labeling. Panels A, B and D show the resulting autoradiographs; panels C and E are immunoblots of B and D respectively, reacted with anti- APH-I sera and 125j staph A protein. In panels A, B and D, the uppermost arrow shows the position of β-isopropyl malate dehydrogenase (i.e., the LEU2 encoded protein expected to be hyperproduced by cells transformed with either pDG150 or pER7.14). The arrow at the right bottom corner indicates a protein obtained only in panel B (pDG150) which corresponds to the expression product of mtAPH-I, and the arrow at the left center in panel D (pER7.14) indicates the protein positioned at the correct molecular weight and charge for the ENOl::mtAPH-I fusion. Thus the fusion protein is shown to have not only an increased MW above mtAPH-I, but to bear the expected differing charge as well. Note absence of unfused mtAPH-I spot in panel D indicating the fusion protein per se is responsible for the dominant selectable activity encoded by pER7.14. Panels D and E each show only a single spot corresponding to ιl25 anti-APH-I i'mmunoreactive labeling designated by the arrow; the remaining 35 S spots serving to orient and verify its position. The 125j s ot in panel C corresponds to the mtAPH-I spot indicated in panel B, and that in panel E to the fusion protein in panel D, as expected. Again, note the absence of unfused mtAPH-I immunoreactive spot in panel E. Western analysis of the extracts of yeast strain S173-6B transformed with the LEU2 fusions further confirmed production of proteins of the expected molecular weights as shown in figure 11. In that figure lanes A, B, C and E correspond to extracts of cells transformed with pLR82.90, pLR82.88, pLR51.57 and pLRll.17, respectively. The extracts seen in lanes D and F are of untransformed yeast, that in lane F was also spiked with purified mtAPH-I. (Lane G contains size markers.) As expected, the mtAPH-I standard corresponds to a MW of >30,000; no protein of this MW is seen in lanes A, B, C and E, indicating the fusion proteins per se are responsible for the high level dominant selectable activity encoded by the four fusion plasmids. The fusion proteins in these lanes give the expected MWs of ca. 39.1, 38.9, 36.0, and 31.7 kD, respectively. The molecular weight difference between the proteins produced in pLR82.90 and pLR82.88 is perceptible on the gel although this represents a difference of only ca. 230 daltons. F - Construction of a Donor Plasmid for a Portable Pτ. τ* F$ .g EcoRI/Hindlll Pre-ATG Cassette The mtAPH-I gene was used as a convenient marker for the construction of a cassette. First, a DNA sequence containing the Pχ_ λ ' phage promoter and the ribosome binding site for the N-gene (N j ^g) was obtained from a derivative of pRC30 described by Shimatake and Rosenberg, Nature (1981) 292:128. pRC30 contains a 2.34 kb fragment from λ phage cloned into the HindHI/BamHI vector fragment from pBR322. The P L promoter and NRBS occupy a segment in pRC30 between a Bglll and Hpal site. The derivative has the Bglll site converted to an EcoRI site. The Bglll site immediately preceding the P L promoter was converted into an EcoRI site as follows: pRC30 was digested with Bglll, repaired with Rlenow and dNTPs,- and ligated with T4 ligase to an EcoRI linker (available from New England Biolabs) and transformed into E. coli strain MM294 Lambda + . Plasmids were isolated from Amp R TetS transformants and the desired sequence was confirmed by restriction enzyme analysis. The resulting plasmid, pFC3, was double-digested with Pvul and Hpal to obtain an approximately 540 bp fragment framing the desired sequence. This fragment was partially digested with Hinfl and the 424 bp fragment isolated and treated wiih Rlenow and dATP, followed by SI nuclease, to generate a blunt- ended fragment with 3' terminal sequence -AGGAGAA where the -AGGAGA portion is the -^g. This fragment was treated with EcoRI to give a 347 base pair DNA fragment with 5'- EcoRI/HinfI(partial repair, SI blunt)-3' termini. To obtain a plasmid containing desired EcoRI/ Hindlll cassette containing PL BS' tne resu lting fragment was ligated into an EcoRI/HindIII(repaired) cleaved plasmid vector fragment obtained from pDG144. Accordingly, pDG144 was digested with Hindlll, blunt-ended with Rlenow and dNTPs, and then digested with EcoRI. The vector fragment was ligated with the above- prepared EcoRI/HinfI(repaired) fragment and transformed into MC1000-39531. Amp R Ran R colonies were selected, plasmids isolated and the correct sequence construction was verified by restriction analysis and sequencing. One plasmid containing the correct sequence was designated •P L Ran. An alternative vector to provide the promoter- RBS cassette, pFC5, uses the lac-Z fusion flag as a marker for successful construction. pβI-Z15, deposited 13 January 1984, ATCC No. 39578, was prepared by fusing a sequence containing ATG plus 140 bp of β -IFN fused to lac-Z into pBR322. In pβI-Z15, the EcoRI site of pBR322 is retained, and the insert contains a Hindlll site immediately preceding the ATG start codon. pβI-Z15 was restricted with Hindlll, repaired with Rlenow and dNTPs, and then digested with EcoRI. The resulting EcoRI/ HindΙII(repaired) vector fragment was ligated with the EcoRI/HinfI(repaired) fragment above. The ligation mixture was used to transform MC1000-39531 and Amp R transformants containing the successful construction were identified by ability to grow on lactose minimal plates at 34°C but not at 30°C. (Transformations were plated on X-gal-Amp plates at 30° and 34° and on minimal-lactose plates at 30° and 34°. Transformants with the proper construction are blue on x-gal-Amp plates at both temp¬ eratures, but grow on minimal lactose plates only at 34°.) The successful construct was designated pFC5. pFC5 or pPi- n and analogous vectors constructed so as to contain this cassette along with an appropriate marker and replicon, may be used to clone and provide a source for the EcoRI/HindlH fragment. The cassette can then conveniently be placed into an expression vector for a desired sequence behind an ATG start codon for the sequence where this codon contains a Hindlll site proximately preceding it. G. Construction of Vectors Providing the PT^ B- "" ATG Cassette - PPT.NRBS ATG and pDG141(Pτ. ) The PLNRBS cassette may also be provided with an operably linked ATG start codon by ligation of the des-ATG cassette into a suitable host vector. pBW20, a derivative of pBR322 containing a synthetic sequence providing an ATG start codon an appropriate distance downstream from a Hindlll site, can be thus used. * To prepare pBW20, pBR322 was digested with Hindlll, repaired with Rlenow and the four dNTPs, then digested with PvuII. The vector fragment was then ligated in a standard blunt-end ligation with the self- complementary dodecamer TATGAGCTCATA, which contains a SacI recognition site partially overlapping and downstream from the ATG sequence. The ligation mixture was transformed into E. coli MM294, and correct construction confirmed by isolation of the plasmids and Maxam-Gilbert sequencing. The resulting pertinent sequence in pBW20 is as follows: Hindlll SacI To prepare PP L N RB s ATG, pP L Ran was digested with Hindlll and EcoRI and ligated to the EcoRI/HindlH digested BAPed vector fragment from ρBW20, transformed into E. coli MC1000-39531. Amp R colonies were selected, and the desired vector construction was confirmed by sequencing or restriction enzyme analysis. One cloned colony containing the correct construction, PP^ RBS ATG f thus provides a source for a P L N RBS~ ATG cassette in a host plasmid suitable for insertion of a gene sequence desired to be expressed. The properly restricted host vector containing the cassette can be provided by digestion with SacI, blunt ending with Rlenow or SI nuclease, and insertion of the blunt-ended gene. pDG141, deposited in the ATCC on 24 January 1984, and given accession number 39588, can also provide the ATG for ' the P N RB S-ATG cassette. pDG141 contains the • same dodecamer insert as ρBW20 in front of a trp promoter cassette. Thus, following the procedure of the previous paragraph, but substituting for pBW20, pDG141, the analogous plasmid pDG141(P L ) is obtained. H. Use of the Pf. ηηc; Cassette in Expression The following examples illustrate one aspect of the invention by describing the construction of expression vectors suitable for production of IL-2 and the successful expression of the appropriate coding sequences. IL-2 and its modified forms are members of a class of proteins designated lymphokines which are useful in therapy directed against deviant cell metabolism. Of course, any desired peptide could be analogously produced by providing the appropriate coding sequence in a manner analogous to that illustrated for production of IL-2. Further, rather than the P^ RBS cassette, the P L RBS ATG cassette could be placed in front of the codons for the desired peptide as described above. Native IL-2 is a 133 amino acid sequence with an alanine at its N-terminus. For expression in procaryotic systems, the codons of the leader sequence in the native gene are replaced by an ATG, resulting in production of protein having a methionine residue at the N-terminus. In the paragraphs below,, a 133 amino acid modified IL-2 sequence with N-terminal methionine, lacking the native N-terminal alanine, and containing serine at position 125 designated herein IL-2 des-ala, serl25 is produced under control of the cassette of the invention. Alternate IL-2 constructions employing this cassette, such as that set forth in paragraph H.3, or constructions involving other forms of IL-2 can, of course, be made. Construction of pFC54 pFC54 is an expression vector for a modified form of IL-2 wherein the cysteine at position 125 has been replaced by a serine residue (IL-2 des-ala, serl25). It is constructed using ρFC5 as a source of the PLNRBS cassette, pLW46 as a source of the coding sequence, and pCS4 as a source of the high copy number replicon, as follows: pCS4 (see below) and pFC5 were each digested with EcoRI and Hindlll and the digests ligated at 1:2 molar ratio, 60 μg/ml under sticky end conditions. The ligated DNA (150 ng) was used to transform MC1000-39531 to Amp R , and Lac" transformants screened for the desired 5.45 kb plasmid. The correct plasmid, pFC8, contained the desired 346 bp EcoRI/Hindlll PLNRBS fragment in place of the 110 bp trp control region of pCS4. PLW46 contains the coding sequence for a mutein IL-2 (des-ala, serl25) as a unique Hindlll/Banll fragment. This plasmid transformed into E. coli MM294 was deposited 26 September 1983 and assigned ATCC no. 39452. pLW46 was digested to completion with PvuII (to cleave the unwanted fragment), Hindlll and Banll. pFC8 was also digested to completion with- Hindlll and Banll. The digests were mixed (4:1 molar ratio, 50 μg/ml DNA), ligated under sticky end conditions, and the mixture (100 ng DNA) was used to transform MC1000-39531 to Amp R . Successful transformants were screened for the desired 5.4 kb plasmid lacking the PstI site of pLW46, containing a unique Xbal site, a unique Hindlll site, and yielding a 526 bp EcoRI/Xbal fragment. The desired plasmid was designated pFC54. Its construction is summarized in Figure 12. ' ρFC54 transformed into E. coli DG95 lambda lysogen was deposited in the CMCC as no. 2015, and was deposited with the ATCC on 4 September 1984 and has accession no. 39831. Construction of pCS4 pCS4 was constructed from pCS3, a plasmid containing a temperatue-sensitive high copy number replicon, by replacing the smaller EcoRI/BamHI digest fragment from pCS3 with an EcoRI/XhoII digest fragment which contains the trp promoter/3IFN coding sequence obtained from the plasmid p ltrp3-4-l which was deposited with ATCC 30 March 1984 and has accession no. ATCC 39646. pCS3 was deposited with ATCC 3 June 1982 and has accession no. ATCC 39142. Production of IL-2 des-ala, ser125 pFC54 was transformed into E. coli DG95 lambda lysogen and the transformants were grown and induced as follows: Fresh overnight samples of pFC54/DG95 were inoculated into N8-2 media (per 500 mis: 20 mM NH4CI, 44 mM RH 2 P04, 56.2 mM Na2HP04, 18 mM R2SO4, 0.4 mM gSθ4, 6 M ZnS04, 6 μM MnS04, 0.2 μM CUSO4, 0*4% glucose, 0.002% thiamine) supplemented with 5 g/1 casamino acid, 5 μg/1 glucose, 100 μg/ml ampicillin and 10 μM FeS04- T e cells were grown at 30°C to an OD 680 of 0.150, and then induced by raising the temperature. These transformants produced IL-2, des-ala, serl25 as 20% of accumulated total cell protein after 1-2 hr of induction at 40°C. To assess the level of production, 0.5 ml of cells were centrifuged and the pellet was resuspended in 20 μl 3% SDS, 62.5 mM Tris- HC1, pH 6.8. Following heating at 95°C for 5 minutes the samples were run on 12.5% SDS polyacrylamide 3% stacking gel. The production level was then assayed by the intensity of Coomassie Blue stained SDS-polyacrylamide gels. The activity of the IL-2 produced was verified using standard assay methods. Construction of pFC53 An IL-2 sequence having 134 amino acid residues, differing from that above by the presence of an alanine residue immediately after the methionine encoded by an ATG start codon (the normal N-terminus in the native sequence) can be obtained in a manner exactly analogous to that set forth in the previous illustration. The coding sequence for this protein, designated herein IL-2 serl25 is obtained as a Hindlll/Banll fragment containing the coding sequence from pLW55. (pLW55 in MC1000-39531 was deposited with the ATCC 18 November 1983 and given accession number 39516.) The resulting plasmid containing the temperature sensitive high copy number replicon from ρCS4 and the LNRBS cassette of the invention from pFC5 was designated pFC53. Transformation of pFC53- into E. coli DG95 lambda lysogen resulted in cultures which produced IL-2 serl25. The following plasmids have' been deposited at the American Type Culture Collection, Rockville, Maryland, U.S.A. (ATCC) under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulations thereunder (Budapest Treaty) and are thus maintained and made available according to the terms of the Budapest Treaty. Availability of such strains is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws. The deposited plasmids have been assigned the indicated ATCC deposit numbers. The plasmids have also been deposited with the Master Culture Collection (CMCC) of Cetus Corporation, Emeryville, California, U.S.A., the assignee of the present application, and assigned the indicated CMCC deposit numbers: Plasmid CMCC Deposit No. ATCC No. pDG144 1960 39579 PFC19 • 1832 39551 PDG149 1928 20694 PDG148 1929 20695 pDG141 1966 39588 pFC5 1935 39864 pFC54 2015 39831 pCS3 —— 39142

Claims: Claims 1. A portable, regulatable control cassette for expression of a protein sequence in procaryotes which cassette comprises: a first DNA sequence which is the P L promoter operably linked to a second DNA sequence corresponding to N j -^g upstream of 'a third DNA sequence having at least one restriction site which permits cleavage within 6 bp 3' of the ^ sequence. 2. A portable, regulatable control cassette for expression of coding sequences in procaryotic hosts which comprises a first DNA sequence which is the Pχ_ promoter operably linked to a second DNA sequence corresponding to NRBS' b° h aforesaid DNA sequences operably linked to an ATG start codon, all upstream of a third DNA sequence having a restriction site which permits cleavage within 6 bp 3 ' of the G of the ATG start codon. 3. Cells or cell cultures, transformed with a vector which comprises the cassette of claim 1 operably linked to said coding sequence, and wherein the coding sequence is preceded by a start codon. 4. Cells or cell cultures transformed with a vector which comprises the cassette of claim 2 operably linked to said coding sequence. 5. Cells or cell cultures of claim 3 or 4 wherein the vector further includes an origin of replication regulated by temperature. 6. Cells or cell cultures of claim 3, 4 or 5 wherein the desired coding sequence -encodes IL-2 or mutein thereof. 7. A method of producing a desired protein which comprises culturing the transformed cells of claim 3 or 4 and recovering the desired protein therefrom. 8. The method of claim 7 wherein the desired protein is IL-2. 9. A protein produced by the method of claim 8. 10. A portable DNA sequence encoding a dominant selectable marker effective in procaryotic and eucaryotic transformants which comprises: an ATG start codon in reading frame with the codons of the mtAPH-I gene and at least one cassette-unique restriction site upstream of and proximal to the ATG start codon. 11. Recombinant host cells transformed with an expression vector capable of conferring resistance to G418 on a procaryotic or eucaryotic transformant which vector comprises an ATG start codon in reading frame with the codons of the mtAPH-I gene, all operably linked to appropriate control sequences suitable to the host harboring the vector. 12. The recombinant host cells of claim 11 wherein the vector further contains, proximally upstream of the mtAPH-I codons, at least one 5' flanking restriction site. 13. The recombinant host cells of claim 11 wherein the vector further contains a desired coding sequence in reading frame with the mtAPH-I codons so as to encode a fusion protein which comprises a desired peptide as the N-terminal sequence and mtAPH-I as the C- terminal sequence. 14. A method of selecting successful transformants among eucaryotic cells which comprises selecting G418 resistant colonies among cells which have been treated with the vector constructed from the DNA sequence of claim 10. 15. A fusion protein which comprises an N- terminal sequence comprising the N-terminal amino acid sequence of a desired protein and a C-terminal sequence comprising mtAPH-I. 16. A fusion protein which is operable as a dominant selectable marker in lacY~ cells and which has quantifiable enzymic activity. 17. A fusion protein which comprises a desired sequence portion and a fusion flag portion wherein the fusion flag portion is operable as a dominant selectable marker in lacY" cells and has quantifiable enzymic activity. 18. The protein of claim 17 wherein said fusion flag portion is mtAPH-I. 19. A recombinant DNA sequence which encodes the fusion protein of claim 17. 20. A host cell transformed with the sequence of claim 19. 21. A method of diagnosing effectiveness of an expression system which comprises quantifying the enzymic activity of the protein of claim 17. 22. A method for selecting' successful transformants which comprises plating DNA-treated host cells on media selective for cells which produce the protein of claim 17.

Inventors: GELFAND DAVID H, LAWYER FRANCIS C, STOFFEL SUSANNE, GELFAND, DAVID, H., LAWYER, FRANCIS, C., STOFFEL, SUSANNE
Applicants: CETUS CORP, CETUS CORPORATION
Application year: 1985
Main classification: C12N15
IPC codes: C07K14, C07K19, C12N1, C12N9, C12N15, C12P21, C12Q1, C12R1